FEATURE_phases list | FEATURE_enrollmentCount int64 | FEATURE_allocation string | FEATURE_interventionModel string | FEATURE_primaryPurpose class label | FEATURE_masking class label | FEATURE_healthyVolunteers bool | FEATURE_sex class label | FEATURE_oversightHasDmc bool | FEATURE_briefSummary string | FEATURE_detailedDescription string | FEATURE_conditions string | FEATURE_conditionsKeywords string | FEATURE_protocolPdfText string | FEATURE_numArms int64 | FEATURE_armDescriptions string | FEATURE_armGroupTypes list | FEATURE_numInterventions int64 | FEATURE_interventionTypes list | FEATURE_interventionDescriptions string | FEATURE_interventionNames string | FEATURE_numLocations int64 | FEATURE_locationDetails string | LABEL_ct_level_ade_population int64 | LABEL_sum_dosing_errors int64 | LABEL_dosing_error_rate float32 | LABEL_wilson_label int64 | METADATA_nctId string | METADATA_overallStatus class label | METADATA_completionDate date32 | METADATA_startDate date32 | METADATA_leadSponsorName string | METADATA_leadSponsorClass class label | METADATA_hasProtocol bool | METADATA_hasSap bool | METADATA_hasIcf bool | METADATA_protocolPdfLinks string | METADATA_count_Accidental drug intake by child int64 | METADATA_count_Accidental overdose int64 | METADATA_count_Accidental overdose (therapeutic agent) int64 | METADATA_count_Accidental underdose int64 | METADATA_count_Deliberate overdose int64 | METADATA_count_Dose calculation error int64 | METADATA_count_Drug administration error int64 | METADATA_count_Drug overdose int64 | METADATA_count_Drug overdose accidental int64 | METADATA_count_Extra dose administered int64 | METADATA_count_Incorrect dosage administered int64 | METADATA_count_Incorrect dose administered int64 | METADATA_count_Incorrect drug administration duration int64 | METADATA_count_Incorrect drug administration rate int64 | METADATA_count_Incorrect product administration duration int64 | METADATA_count_Intentional overdose int64 | METADATA_count_Medication error int64 | METADATA_count_Medication monitoring error int64 | METADATA_count_Multiple drug overdose int64 | METADATA_count_Multiple drug overdose accidental int64 | METADATA_count_Multiple drug overdose intentional int64 | METADATA_count_Multiple use of single-use product int64 | METADATA_count_Non-accidental overdose int64 | METADATA_count_Overdose int64 | METADATA_count_Overdose NOS int64 | METADATA_count_Overmedication int64 | METADATA_count_Prescribed overdose int64 | METADATA_count_Treatment noncompliance int64 | METADATA_count_Underdose int64 | METADATA_count_Unintentional medical device removal int64 | METADATA_count_Unintentional medical device removal by patient int64 | METADATA_wilson_lower_bound float32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
0
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | Background: The J-Tip Device allows an intradermal needle-free jet injection of 1% buffered lidocaine. This study compares needle-free jet injection of lidocaine to saline in reducing pain prior to lumbar puncture in infants.
Methods: Randomized, double-blinded, placebo controlled trial involving infants, less than 3 ... | Background: Lumbar puncture is an essential procedure in the emergency department for the evaluation of meningitis. Subcutaneous injection of lidocaine prior to lumbar puncture for local anesthesia is not a pain free procedure. The J-Tip Device allows an intradermal needle-free jet injection of 1% buffered lidocaine. T... | Pain | pain lidocaine lumbar puncture j-tip | null | 2 | arm 1: Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline) arm 2: Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine | [
0,
2
] | 1 | [
0
] | intervention 1: All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded | intervention 1: Buffered Lidocaine J-tip | 1 | Phoenix | Arizona | United States | -112.07404 | 33.44838 | 60 | 0 | 0 | 0 | NCT01224431 | 1COMPLETED | 2010-06-01 | 2009-06-01 | Phoenix Children's Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 48 | RANDOMIZED | FACTORIAL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | Hypothesis: Ropivacaine, morphine and ketorolac injected after knee arthroscopy is as effective as this solution plus ropivacaine administered intra-articularly for twenty-four hours.
Three groups were assigned random patients, each group provided a different method of pain medication in order to determine the effecti... | Arthroscopic knee patients were randomized to 1 of 3 groups. A) 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour; B) an identical solution plus a pain pump containing 100-mL of normal saline administered ... | Pain | null | 3 | arm 1: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour; arm 2: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline admin... | [
0,
1,
1
] | 3 | [
1,
1,
0
] | intervention 1: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour intervention 2: 30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of nor... | intervention 1: pain pump containing ropivacaine intervention 2: saline pain pump with injectable medication intervention 3: ropivacaine, ketorolac , morphine sulfate | 0 | null | 48 | 0 | 0 | 0 | NCT01242644 | 1COMPLETED | 2010-06-01 | 2006-10-01 | University of South Alabama | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 158 | RANDOMIZED | CROSSOVER | 1PREVENTION | 0NONE | true | 1FEMALE | true | For the contraceptive application a film-coated tablet has been developed which combines nomegestrol acetate (NOMAC) with estradiol (E2). This was an open-label, randomized, single-dose, four-way, replicate, cross-over study design conducted in 2 parallel parts at two sites, one site per study part. The primary objecti... | null | Healthy Postmenopausal Females | null | 4 | arm 1: Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Partic... | [
0,
1,
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods intervention 2: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program ("Batch A") orally in the morning on Day 1 for all periods intervention 3: 1... | intervention 1: Commercial NOMAC-E2 intervention 2: Phase 3 NOMAC-E2 "Batch A" intervention 3: Phase 3 NOMAC-E2 "Batch B" | 0 | null | 301 | 0 | 0 | 0 | NCT01345786 | 1COMPLETED | 2010-06-01 | 2009-11-01 | Organon and Co | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 3 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Background:
* One way tumors are able to grow is by forming new blood vessels that supply it with nutrients and oxygen.
* Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the formation of new blood vessels.
* Blocking these p... | Background:
* von Hippel-Lindau (VHL) inactivation by mutation or promoter hypermethylation is seen in a high proportion of sporadic clear cell renal cancers.
* Inactivation of VHL leads to accumulation of proteins targeted for degradation through the ubiquitin pathway, which includes a group of transcriptionally acti... | Advanced Clear Cell Renal Carcinoma | Advanced Clear Cell Renal Cell Carcinoma Cancer Renal Renal Cell Carcinoma Kidney Cancer | null | 1 | arm 1: Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived gro... | [
5
] | 1 | [
0
] | intervention 1: Daily dose 300mg/day by mouth, 28 day cycle | intervention 1: vandetanib | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 3 | 0 | 0 | 0 | NCT01372813 | 6TERMINATED | 2010-06-01 | 2007-12-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 38 | RANDOMIZED | PARALLEL | 7BASIC_SCIENCE | 3TRIPLE | true | 0ALL | false | The investigators tested whether pain decrease can be observed centrally with non-invasive brain imaging in CBP subjects receiving Lidoderm. The investigators first tested effects of 5% Lidoderm patched in an open labelled trial. Next the investigators compared the effects of Lidocaine versus Placebo patches. Three tim... | Previous data showed that Lidoderm patches that contain 5% Lidocaine applied to the affected area for a period of 1-2 weeks decreased chronic pain. We conducted a preliminary open-label trial in chronic back pain patients and found that the patients reported reduction in pain intensity and associated brain activity (me... | Low Back Pain | chronic back pain placebo fmri brain imaging | null | 2 | arm 1: 5% lidoderm patch arm 2: placebo patch | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 5% lidoderm patch intervention 2: placebo | intervention 1: lidocaine intervention 2: placebo | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 38 | 0 | 0 | 0 | NCT01515540 | 1COMPLETED | 2010-06-01 | 2004-01-01 | Northwestern University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 40 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor. | Multicentre, double-blind, randomised, placebo-controlled study in four parallel groups of PD patients treated with standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and with motor fluctuations ("wearing-off" phenomenon) | Parkinson's Disease | Parkinson Disease BIA 9-1067 | null | 4 | arm 1: PLC, Placebo
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half arm 2: 5 mg BIA 9-1067 (OPC, Opicapone)
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half arm 3: 15 mg BIA 9-1067 (OPC, Opicap... | [
2,
0,
0,
0
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: once-daily intervention 2: BIA 9-1067 - 5 mg single-dose intervention 3: BIA 9-1067 - 15 mg single-dose intervention 4: BIA 9-1067 - 30 mg single-dose intervention 5: Levodopa 100 mg Carbidopa 25 mg intervention 6: Levodopa 100 mg Benzerazide 25 mg | intervention 1: Placebo intervention 2: BIA 9-1067 intervention 3: BIA 9-1067 intervention 4: BIA 9-1067 intervention 5: Levodopa/Carbidopa intervention 6: Levodopa/Benzerazide | 7 | Brasov | N/A | Romania | 25.60613 | 45.64861
Bucharest | N/A | Romania | 26.10626 | 44.43225
Craiova | N/A | Romania | 23.8 | 44.31667
Dnipropetrovsk | N/A | Ukraine | 35.04066 | 48.46664
Kharkiv | N/A | Ukraine | 36.25475 | 49.98177
Kharkiv | N/A | Ukraine | 36.25475 | 49.98177
Kyiv | N/A | Ukraine | 30.5238 | 50.4546... | 40 | 0 | 0 | 0 | NCT01568047 | 1COMPLETED | 2010-06-01 | 2010-02-01 | Bial - Portela C S.A. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 77 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | * The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
* A prospective, double-blind, single group, 'within-subject' designed clinical trial of 77 diagnosed T2DM pati... | 1. Introduction Thiazolidinediones and metformin are known drugs and especially metformin is widely used medicine to treat people with T2DM. Though pioglitazone has been suspended in many countries, its safety and efficacy is a matter of research for the drug investigators. Thiazolidinediones had been introduced in 199... | Type 2 Diabetes Mellitus | Bangladesh T2DM Pioglitazone Metformin Insulin secretion and Sensitivity | null | 2 | arm 1: The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months arm 2: The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months. | [
0,
0
] | 2 | [
0,
0
] | intervention 1: 77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month. intervention 2: After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin ta... | intervention 1: Pioglitazone hydrochloride intervention 2: Metformin hydrochloride | 1 | Dhaka | Dhaka Division | Bangladesh | 90.40744 | 23.7104 | 147 | 0 | 0 | 0 | NCT01589445 | 1COMPLETED | 2010-06-01 | 2008-11-01 | University of Dhaka | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 60 | RANDOMIZED | PARALLEL | 7BASIC_SCIENCE | 2DOUBLE | true | 1FEMALE | false | The purpose of this study is to determine if a single dose of LY2541546 has any side effects on the body and to determine how long and how much LY2541546 stays in the bloodstream of the body. | null | Healthy | Postmenopausal females Volunteers | null | 9 | arm 1: Single dose of 7.5 mg LY2541546 administered intravenously (IV) arm 2: Single dose of 25 mg LY2541546 administered IV arm 3: Single dose of 75 mg LY2541546 administered IV arm 4: Single dose of 225 mg LY2541546 administered IV arm 5: Single dose of 750 mg LY2541546 administered IV arm 6: Single dose of 150 mg LY... | [
0,
0,
0,
0,
0,
0,
2,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Administered IV intervention 2: Administered SC intervention 3: Administered IV or SC | intervention 1: LY2541546 - IV intervention 2: LY2541546 - SC intervention 3: Placebo | 2 | Evansville | Indiana | United States | -87.55585 | 37.97476
Indianapolis | Indiana | United States | -86.15804 | 39.76838 | 60 | 0 | 0 | 0 | NCT01742078 | 1COMPLETED | 2010-06-01 | 2008-06-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 452 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This was a multinational, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple doses of ESL as prophylactic treatment in subjects with migraine with or without aura. Subjects were randomised in a 1:1:1 ratio to receive placebo, ESL 800 mg/day ... | The study consisted of a Screening Period of 2 to 4 weeks, a 4-week placebo Baseline Period, a 2-week Titration Period, a 12-week Maintenance Period, and a 4-week Follow-up Period. During the entire study the subjects had a diary to document the occurrence, duration, and intensity of headaches, the occurrence or not of... | Migraine | migraine; ESL; eslicarbazepine acetate | null | 3 | arm 1: eslicarbazepine acetate 1200 mg arm 2: eslicarbazepine acetate 800 mg arm 3: Placebo tablets | [
1,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: Tablets intervention 2: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route. intervention 3: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1... | intervention 1: Placebo intervention 2: ESL 1200 mg intervention 3: ESL 800 mg | 0 | null | 410 | 0 | 0 | 0 | NCT01820559 | 1COMPLETED | 2010-06-01 | 2009-04-01 | Bial - Portela C S.A. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 7 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe asthma with elevated sputum neutrophils. | null | Asthma | Sputum cell counts Neutrophils Severe Asthma ICS Inhaled corticosteroids | null | 2 | arm 1: 12 day repeat dosing with placebo arm 2: 12 day repeat dosing treatment phase with 100mg GSK2190915. | [
2,
0
] | 2 | [
0,
0
] | intervention 1: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. intervention 2: Placebo :
2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10) | intervention 1: GSK2190195 100mg intervention 2: Placebo | 8 | Hamilton | Ontario | Canada | -79.84963 | 43.25011
Kingston | Ontario | Canada | -76.48098 | 44.22976
Montreal | Quebec | Canada | -73.58781 | 45.50884
Sainte-Foy | Quebec | Canada | -71.29217 | 46.78139
Glasgow | Lanarkshire | United Kingdom | -4.25763 | 55.86515
Leicester | Leicestershire | United Kingdom | -1.13169 ... | 7 | 0 | 0 | 0 | NCT00850642 | 6TERMINATED | 2010-06-02 | 2009-06-26 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3,
4
] | 53 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose | Uncontrolled study | Herpes Labialis | Herpes labialis cold sores herpes simplex type 1 | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose. | intervention 1: Famciclovir | 12 | San Diego | California | United States | -117.16472 | 32.71571
Chicago | Illinois | United States | -87.65005 | 41.85003
Evansville | Indiana | United States | -87.55585 | 37.97476
St Louis | Missouri | United States | -90.19789 | 38.62727
Rochester | New York | United States | -77.61556 | 43.15478
Cincinnati | Ohio | ... | 106 | 0 | 0 | 0 | NCT00878072 | 1COMPLETED | 2010-06-02 | 2009-03-25 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 1 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients with relapsed ALL who have developed an allergy to the E. coli formulation. This study will administer the drug intravenously instead o... | Significance
1. Substitution of Erwinase after E.coli asparaginase allergy has been standard practice despite the paucity of evidence regarding its efficacy and uncertainty about dose. Definition of an appropriate dose and schedule of Erwinase that provides reliable asparagine depletion may be useful for patients with... | Relapsed Acute Lymphoblastic Leukemia Allergy to PEG e.Coli Asparaginase Allergy to Native e.Coli Asparaginase | Relapsed Allergy Erwinia Acute Lymphoblastic Leukemia | null | 1 | arm 1: All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal... | [
0
] | 8 | [
0,
0,
0,
0,
0,
0,
0,
0
] | intervention 1: The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.
Erwinase will be administered as a 2-hour intravenous infusion. intervention 2: 1.5 mg/m2/dose IV push (maximum single dose 2 mg)... | intervention 1: Erwinase intervention 2: Vincristine intervention 3: Dexamethasone intervention 4: Doxorubicin intervention 5: Cytarabine intervention 6: Methotrexate intervention 7: Triple Intrathecal Therapy intervention 8: Dexrazoxane | 1 | Los Angeles | California | United States | -118.24368 | 34.05223 | 1 | 0 | 0 | 0 | NCT00928200 | 6TERMINATED | 2010-06-04 | 2009-04-13 | Therapeutic Advances in Childhood Leukemia Consortium | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 183 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle. | Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate. | Epithelial Ovarian Cancer | second line treatment platinum resistant ovary ovaries cancer epithelial carcinomas tumor | null | 1 | arm 1: All patients will receive voreloxin injection | [
0
] | 1 | [
0
] | intervention 1: All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable. | intervention 1: Voreloxin Injection | 20 | Scottsdale | Arizona | United States | -111.89903 | 33.50921
Newport Beach | California | United States | -117.92895 | 33.61891
San Diego | California | United States | -117.16472 | 32.71571
Stanford | California | United States | -122.16608 | 37.42411
Washington D.C. | District of Columbia | United States | -77.03637 ... | 274 | 0 | 0 | 0 | NCT00408603 | 1COMPLETED | 2010-06-09 | 2006-12-20 | Sunesis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 44 | NA | SINGLE_GROUP | 4SUPPORTIVE_CARE | 0NONE | false | 0ALL | false | This phase II trial studies the side effects and how well sirolimus works as secondary therapy in treating patients with chronic graft-versus-host disease (GVHD) that did not respond to prior treatment. Sirolimus may be an effective treatment for chronic GVHD | PRIMARY OBJECTIVES:
I. To assess the safety of sirolimus administered at a dose which provides steady-state, whole blood trough levels of 5-10 ng/mL in patients with chronic GVHD.
II. To determine whether administration of sirolimus provides benefit for patients with chronic GVHD that has not responded adequately to ... | Graft Versus Host Disease | null | 1 | arm 1: Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is s... | [
0
] | 1 | [
0
] | intervention 1: Given PO | intervention 1: sirolimus | 1 | Seattle | Washington | United States | -122.33207 | 47.60621 | 44 | 0 | 0 | 0 | NCT00079183 | 1COMPLETED | 2010-06-10 | 2002-04-01 | Fred Hutchinson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 481 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days. In addition to an optimized background regimen (OBR), participants will be randomized to receive:
* 100 mg OPC-67683 twice daily (BID)
* 200 mg OPC-67683 BID
* Placebo BI... | This is a multi center, randomized, double-blinded, stratified, placebo-controlled clinical trial in three parallel groups. Participants will be randomized to one of the following three treatment groups:
* OBR plus 100 mg OPC-67683 BID
* OBR plus 200 mg OPC-67683 BID
* OBR plus placebo BID
The three treatment groups ... | Tuberculosis, Pulmonary Tuberculosis, Multidrug Resistant Extensively Drug-Resistant Tuberculosis | Tuberculosis Pulmonary Multidrug resistant Antitubercular Agents OPC 67683 | null | 3 | arm 1: Participants received delamanid 100 milligrams (mg) (two 50 mg tablets), orally, BID with two matching placebo tablets plus optimized background regimen (OBR) for 56 consecutive days (from Day 1 to Day 56).
Participants were administered OBR as directed by the given investigator based on World Health Organizati... | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening. intervention 2: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resista... | intervention 1: Delamanid intervention 2: Optimized Background Regimen (OBR) intervention 3: Placebo | 17 | San Antonio | Texas | United States | -98.49363 | 29.42412
Beijing | N/A | China | 116.39723 | 39.9075
Shanghai | N/A | China | 121.45806 | 31.22222
Cairo | N/A | Egypt | 31.24967 | 30.06263
Tallinn | N/A | Estonia | 24.75353 | 59.43696
Tartu | N/A | Estonia | 26.72509 | 58.38062
Osaka | N/A | Japan | 135.50107 | 34.69... | 481 | 0 | 0 | 0 | NCT00685360 | 1COMPLETED | 2010-06-11 | 2008-05-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 437 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease. | The primary objective in the present study is to confirm whether ACR16 is efficacious in improving voluntary motor function in Huntington's disease based on the Unified Huntington"s Disease Rating Scale (UHDRS) subscale. These symptoms seem to be most important for the functional disability associated with the disorder... | Huntington's Disease | Huntington's Disease | null | 3 | arm 1: Participants will receive a placebo capsule matching to ACR16 once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), placebo capsule will be taken twice daily as 2 separate doses. arm 2: Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (W... | [
2,
0,
0
] | 2 | [
0,
0
] | intervention 1: Capsules will be swallowed whole with water. intervention 2: Capsules will be swallowed whole with water. | intervention 1: ACR16 intervention 2: Placebo | 31 | Graz | Styria | Austria | 15.45 | 47.06667
Innsbruck | Tyrol | Austria | 11.39454 | 47.26266
Leuven | Flemish Brabant | Belgium | 4.70093 | 50.87959
Lille | Hauts-de-France | France | 3.05858 | 50.63297
Toulouse | Midi-Pyrénées Region | France | 1.44367 | 43.60426
Amiens | Picardie | France | 2.3 | 49.9
Marseille | Pro... | 790 | 2 | 0.002532 | 1 | NCT00665223 | 1COMPLETED | 2010-06-14 | 2008-04-24 | Teva Branded Pharmaceutical Products R&D, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000695 |
[
2
] | 76 | RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis | null | Psoriasis | null | 1 | arm 1: None | [
2
] | 1 | [
0
] | intervention 1: SC and IV administration on days 1, 14, 28, and 42 | intervention 1: ILV-094 | 24 | Beverly Hills | California | United States | -118.40036 | 34.07362
Santa Monica | California | United States | -118.49138 | 34.01949
South Miami | Florida | United States | -80.29338 | 25.7076
South Miami | Florida | United States | -80.29338 | 25.7076
Evansville | Indiana | United States | -87.55585 | 37.97476
Indiana... | 76 | 0 | 0 | 0 | NCT00563524 | 1COMPLETED | 2010-06-14 | 2007-12-20 | Wyeth is now a wholly owned subsidiary of Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 234 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression. | null | Bipolar Depression | bipolar depression | null | 3 | arm 1: 0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing. arm 2: 1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing. arm 3: Matching placebo capsules, oral administration, once daily dosing. | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: Drug: cariprazine (0.25 - 0.75 mg/day) intervention 2: Drug: cariprazine (1.5 - 3.0 mg/day) intervention 3: placebo capsules, oral administration, once daily dosing | intervention 1: cariprazine intervention 2: cariprazine intervention 3: placebo | 26 | Encino | California | United States | -118.50119 | 34.15917
Garden Grove | California | United States | -117.94145 | 33.77391
National City | California | United States | -117.0992 | 32.67811
Newport Beach | California | United States | -117.92895 | 33.61891
Oceanside | California | United States | -117.37948 | 33.1958... | 227 | 0 | 0 | 0 | NCT00852202 | 1COMPLETED | 2010-06-15 | 2009-06-30 | Forest Laboratories | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 82 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate... | null | Hemophilia A | null | 2 | arm 1: Standard prophylaxis arm 2: PK-driven prophylaxis | [
1,
0
] | 2 | [
0,
0
] | intervention 1: Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator intervention 2: PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data | intervention 1: Antihemophilic factor, recombinant, manufactured protein-free intervention 2: Antihemophilic factor, recombinant, manufactured protein-free | 29 | Los Angeles | California | United States | -118.24368 | 34.05223
Chicago | Illinois | United States | -87.65005 | 41.85003
Indianapolis | Indiana | United States | -86.15804 | 39.76838
Minneapolis | Minnesota | United States | -93.26384 | 44.97997
New York | New York | United States | -74.00597 | 40.71427
Oklahoma City... | 140 | 0 | 0 | 0 | NCT00243386 | 1COMPLETED | 2010-06-16 | 2006-01-04 | Baxalta now part of Shire | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 328 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a Major Depressive Disorder, whose symptoms are considered moderate or severe.
Following an init... | The purpose of the current study is to test the safety and the anti-depressant effects of orvepitant, an investigational antidepressant. Efficacy will be assessed using standard depression symptom and severity rating scales (questionaires). The Hamilton Depression Rating Scale (HAM-D) will serve as the primary measure ... | Depressive Disorder, Major | depression QIDS-SR HAMD-17 orvepitant MDD neurokinin-1 antagonist double-blind Phase II randomized efficacy placebo safety | null | 3 | arm 1: inactive placebo to match orvepitant 30 and 60 mg dosage forms arm 2: 30 mg/day (low dose) arm 3: 60 mg/day (high dose) | [
2,
0,
0
] | 2 | [
0,
10
] | intervention 1: Neurokinin-1 (NK-1) antagonist intervention 2: inactive placebo to match orvepitant 30 and 60 mg dosage forms | intervention 1: orvepitant intervention 2: placebo | 20 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Scottsdale | Arizona | United States | -111.89903 | 33.50921
Arcadia | California | United States | -118.03534 | 34.13973
Beverly Hills | California | United States | -118.40036 | 34.07362
National City | California | United States | -117.0992 | 32.67811
Uplan... | 328 | 0 | 0 | 0 | NCT00880399 | 6TERMINATED | 2010-06-16 | 2009-03-01 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 150 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 1FEMALE | false | This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder | This is a double-blind placebo controlled study to assess the CRF1 receptor antagonist, GSK561679, for treatment of depression in adult females diagnosed with Major Depressive Disorder (MDD). A treatment regimen of 350mg/day will be utilized to assess both efficacy and tolerability. Subjects will be randomized in equal... | Depressive Disorder, Major | Depressive Disorder, Major | null | 2 | arm 1: Double blind GSK561679 arm 2: Double blind placebo | [
0,
2
] | 2 | [
0,
10
] | intervention 1: GSK561679 intervention 2: Placebo | intervention 1: GSK561679 intervention 2: Placebo | 18 | Cerritos | California | United States | -118.06479 | 33.85835
San Diego | California | United States | -117.16472 | 32.71571
Torrance | California | United States | -118.34063 | 33.83585
Jacksonville | Florida | United States | -81.65565 | 30.33218
Miami | Florida | United States | -80.19366 | 25.77427
Atlanta | Georgi... | 150 | 0 | 0 | 0 | NCT00733980 | 1COMPLETED | 2010-06-18 | 2008-10-02 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 25 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier... | null | Atopic Dermatitis | Skin barrier Atopic Dermatitis Corticosteroid Effects on skin severity and barrier function | null | 1 | arm 1: glucocorticoid cream | [
0
] | 1 | [
0
] | intervention 1: Fluocinonide 0.1% cream topical daily for two weeks | intervention 1: Fluocinonide | 1 | Portland | Oregon | United States | -122.67621 | 45.52345 | 25 | 0 | 0 | 0 | NCT00819507 | 1COMPLETED | 2010-06-21 | 2009-01-01 | Oregon Health and Science University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 343 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a Major Depressive Disorder, whose symptoms are considered moderate or severe.
Following an init... | The purpose of the current study is to test the safety and the anti-depressant effects of orvepitant, an investigational antidepressant. Efficacy will be assessed using standard depression symptom and severity rating scales (questionaires). The Hamilton Depression Rating Scale (HAM-D) will serve as the primary measure ... | Depressive Disorder | depression safety HAMD QIDS-SR NK-1 antagonist efficacy orvepitant placebo MDD video-rating | null | 3 | arm 1: orvepitant 30 mg (low dose) arm 2: orvepitant 60 mg (high dose) arm 3: inactive placebo to match orvepitant 30 mg and 60 mg dosage forms | [
0,
0,
2
] | 2 | [
0,
10
] | intervention 1: neurokinin-1 antagonist intervention 2: Placebo to match orvepitant 30 mg and 60 mg | intervention 1: orvepitant intervention 2: Placebo | 32 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Orange | California | United States | -117.85311 | 33.78779
Denver | Colorado | United States | -104.9847 | 39.73915
Norwich | Connecticut | United States | -72.07591 | 41.52426
Jacksonville | Florida... | 343 | 0 | 0 | 0 | NCT00880048 | 6TERMINATED | 2010-06-21 | 2009-03-11 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 60 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | true | 0ALL | false | This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy matched control participants. The primary hypothesis is that the area under the curve (AUC) (0 to infinity) of vaniprevir for participants... | null | Hepatitis C | null | 6 | arm 1: Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir arm 2: Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir arm 3: Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir arm ... | [
0,
0,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: single dose administration of 300 mg oral tablet intervention 2: single dose administration of 200 mg oral tablet | intervention 1: Vaniprevir 300 mg intervention 2: Vaniprevir 200 mg | 0 | null | 60 | 0 | 0 | 0 | NCT01010906 | 1COMPLETED | 2010-06-21 | 2009-07-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 132 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Patients will receive 4-weekly intravenous injections of Mircera, at a starting dose of 120, 200 or 3... | null | Anemia | null | 1 | arm 1: Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythr... | [
0
] | 1 | [
0
] | intervention 1: 120, 200 or 360 micrograms iv every 4 weeks (starting dose) | intervention 1: methoxy polyethylene glycol-epoetin beta | 20 | Adana | N/A | Turkey (Türkiye) | 35.32531 | 36.98615
Ankara | N/A | Turkey (Türkiye) | 32.85427 | 39.91987
Ankara | N/A | Turkey (Türkiye) | 32.85427 | 39.91987
Ankara | N/A | Turkey (Türkiye) | 32.85427 | 39.91987
Ankara | N/A | Turkey (Türkiye) | 32.85427 | 39.91987
Ankara | N/A | Turkey (Türkiye) | 32.85427 | 39.919... | 131 | 0 | 0 | 0 | NCT00661505 | 1COMPLETED | 2010-06-22 | 2008-05-14 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 75 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints. | null | Osteomyelitis | Osteomyelitis Prosthetic Hip Prosthetic Knee MRSA Osteomyelitis Associated with an Infected Prosthetic Hip or Knee Joint Staphylococci | null | 3 | arm 1: Daptomycin (6 mg/kg every 24 hours \[q24h\]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week). arm 2: Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week). arm 3: Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was admi... | [
0,
0,
1
] | 7 | [
0,
0,
0,
0,
0,
0,
0
] | intervention 1: 6 mg/kg intervention 2: 8 mg/kg intervention 3: 1 gram intervention 4: 6 mg/kg; used only at UK sites intervention 5: 1-2 gram intervention 6: 1-2 gram intervention 7: 1-2 mg | intervention 1: daptomycin intervention 2: daptomycin intervention 3: vancomycin intervention 4: teicoplanin intervention 5: nafcillin intervention 6: oxacillin intervention 7: flucloxacillin | 26 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Englewood | Colorado | United States | -104.98776 | 39.64777
Washington D.C. | District of Columbia | United States | -77.03637 | 38.89511
Tampa | Florida | United States | -82.45843 | 27.94752
Idaho Falls | Idaho | United States | -112.03414 | 43.46658
Chic... | 74 | 0 | 0 | 0 | NCT00428844 | 1COMPLETED | 2010-06-23 | 2007-06-26 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 201 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior trea... | null | Non-small Cell Lung Cancer | Stage IIIB/IV non-small cell lung cancer Non-small cell lung cancer NSCLC Lung Cancer Pralatrexate Erlotinib Tarceva PDX Smoking Smoker | null | 2 | arm 1: Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). arm 2: 150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met. | [
0,
1
] | 4 | [
0,
0,
7,
7
] | intervention 1: Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Red... | intervention 1: Pralatrexate intervention 2: Erlotinib intervention 3: Vitamin B12 intervention 4: Folic Acid | 47 | Bakersfield | California | United States | -119.01871 | 35.37329
San Diego | California | United States | -117.16472 | 32.71571
Port Saint Lucie | Florida | United States | -80.35033 | 27.29393
Chicago | Illinois | United States | -87.65005 | 41.85003
Westwood | Kansas | United States | -94.6169 | 39.04056
Great Falls ... | 198 | 0 | 0 | 0 | NCT00606502 | 1COMPLETED | 2010-06-24 | 2008-01-01 | Spectrum Pharmaceuticals, Inc | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 1 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The primary objective of this protocol is to treat laboratory confirmed cutaneous leishmaniasis with WR 279,396 in military health care beneficiaries. In this study "cutaneous leishmaniasis" is defined as Old World Leishmaniasis if acquired in the Southwest Central Asia/Middle East. | Up to 10 volunteers, who are military health care beneficiaries, with a diagnosis of Old World cutaneous leishmaniasis who have failed pentavalent antimony or are not eligible to be treated with pentavalent antimony, will be treated with WR 279,396 (topical paromomycin-gentamicin-AQIC) twice a day for 20 days. Primary ... | Cutaneous Leishmaniasis | leishmaniasis cutaneous Old World Leishmania major Treatment | null | 1 | arm 1: WR279,396 topically twice a day for 20 days | [
0
] | 1 | [
0
] | intervention 1: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy. | intervention 1: Paromomycin +Gentamicin topical cream | 1 | Washington D.C. | District of Columbia | United States | -77.03637 | 38.89511 | 1 | 0 | 0 | 0 | NCT00657917 | 6TERMINATED | 2010-06-24 | 2006-12-20 | U.S. Army Medical Research and Development Command | 1FED | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 171 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | This 4 arm study in patients with advanced Stage IIIb/IV non-small cell cancer (NSCLC) who failed at least one standard chemotherapy regimen will determine the proportion of patients with progression-free survival at 12 weeks following combination therapy with R1507 and Tarceva or placebo and Tarceva. Patients will be ... | null | Non-Squamous Non-Small Cell Lung Cancer | null | 4 | arm 1: None arm 2: None arm 3: None arm 4: None | [
2,
2,
0,
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: iv 9mg/kg weekly intervention 2: iv 16mg/kg every 3 weeks intervention 3: iv 9mg/kg weekly intervention 4: iv 16mg/kg every 3 weeks intervention 5: 150mg oral daily | intervention 1: Placebo intervention 2: Placebo intervention 3: RG1507 intervention 4: RG1507 intervention 5: erlotinib [Tarceva] | 57 | Beverly Hills | California | United States | -118.40036 | 34.07362
New Port Richey | Florida | United States | -82.71927 | 28.24418
Atlanta | Georgia | United States | -84.38798 | 33.749
Chicago | Illinois | United States | -87.65005 | 41.85003
Glenview | Illinois | United States | -87.78784 | 42.06975
Joliet | Illinoi... | 171 | 0 | 0 | 0 | NCT00760929 | 6TERMINATED | 2010-06-25 | 2008-11-10 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 50 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B HIV-1 infected subjects. | null | HIV Infections | HIV, HIV attachment inhibitor, attachment inhibitor | Prot_000.pdf:
Page:
1
Protocol Number:
AI438006
IND Number:
N/A
Ex-US
Non IND
EUDRACT Number
2009-013657-14
Date:
22-Jun-2009
Revised Date:
08-Mar-2010
Clinical Protocol AI438006
Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics,
Safety and Pharmacokinetics of BMS-663068 in... | 5 | arm 1: All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8. arm 2: All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni \[QHS\]) from Day 1 to Day 8. arm 3: All participants received BMS-663068 1200 mg and RTV... | [
0,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: BMS-663068 will be administered as a tablet formulation intervention 2: Ritonavir will be administered as a capsule. | intervention 1: BMS-663068 intervention 2: Ritonavir | 1 | Berlin | N/A | Germany | 13.41053 | 52.52437 | 50 | 0 | 0 | 0 | NCT01009814 | 1COMPLETED | 2010-06-25 | 2009-11-23 | ViiV Healthcare | 4INDUSTRY | true | true | false | https://cdn.clinicaltrials.gov/large-docs/14/NCT01009814/Prot_000.pdf https://cdn.clinicaltrials.gov/large-docs/14/NCT01009814/SAP_001.pdf | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 132 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This is a 12-week, randomized, multicenter, double-blind, placebo controlled, fixed-dose parallel group study to assess the efficacy and safety of orvepitant (60 mg/day) versus placebo in subjects with a diagnosis of noncombat-related Posttraumatic Stress Disorder (PTSD), whose symptoms are considered moderate or sever... | The purpose of the current study is to test the safety and effects of orvepitant, an investigational drug for the treatment of noncombat-related PTSD.
Efficacy will be assessed using standard symptom and severity rating scales (questionnaires). The Clinicain Adminstered PTSD Scale (CAPS) will serve as the primary meas... | Post-Traumatic Stress Disorder | efficacy double-blind Clinician Administered PTSD Scale placebo Sleep safety CAPS neurokinin-1 antagonist orvepitant PTSD randomized Post traumatic stress disorder Phase II | null | 2 | arm 1: 60 mg/day arm 2: None | [
0,
2
] | 2 | [
0,
10
] | intervention 1: Neurokinin-1 (NK-1) antagonist intervention 2: Inactive placebo to match orvepitant 60 mg dosage form | intervention 1: orvepitant intervention 2: Placebo | 26 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Scottsdale | Arizona | United States | -111.89903 | 33.50921
Beverly Hills | California | United States | -118.40036 | 34.07362
Torrance | California | United States | -118.34063 | 33.83585
Jacksonville | Florida | United States | -81.65565 | 30.33218
Orlando ... | 129 | 0 | 0 | 0 | NCT01000493 | 1COMPLETED | 2010-06-28 | 2009-11-02 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 34 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | This is a multicenter, placebo controlled, parallel group, double-blind, randomized comparison study to evaluate the efficacy and safety of ropinirole IR tablets orally administered for 12 weeks in patients with symptomatic restless legs syndrome associated with Chronic kidney disease (CKD) managed with haemodialysis (... | null | Restless Legs Syndrome | ropinirole haemodialysis restless legs syndrome | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and ente... | intervention 1: Ropinirole immediate release (IR) intervention 2: Placebo | 19 | Aichi | N/A | Japan | 130.62158 | 32.51879
Aichi | N/A | Japan | 130.62158 | 32.51879
Chiba | N/A | Japan | 140.11667 | 35.6
Chiba | N/A | Japan | 140.11667 | 35.6
Fukuoka | N/A | Japan | 130.41667 | 33.6
Hiroshima | N/A | Japan | 132.45 | 34.4
Hokkaido | N/A | Japan | N/A | N/A
Hyōgo | N/A | Japan | 144.43333 | 43.366... | 34 | 0 | 0 | 0 | NCT00996944 | 6TERMINATED | 2010-06-29 | 2009-11-30 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 6 | RANDOMIZED | PARALLEL | 1PREVENTION | 0NONE | false | 0ALL | false | The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer. | Breast cancer is the second most common cause of brain metastases. Overall survival after the development of brain metastases tends to be poor (6-8 months). Over-expression of Human Epidermal Growth Factor Receptor 2 (HER-2/neu), negative estrogen receptor, and young age at diagnosis seem to be indicators of high risk ... | Breast Neoplasm Brain Neoplasm Second Neoplasm | null | 2 | arm 1: None arm 2: None | [
0,
4
] | 1 | [
0
] | intervention 1: Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles | intervention 1: temozolomide | 0 | null | 6 | 0 | 0 | 0 | NCT00638963 | 6TERMINATED | 2010-06-30 | 2008-10-02 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 206 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients. | Participants who completed 48 weeks of the original 48-week double-blind study were invited to continue in two extensions: MK0518-004-10 (NCT00100048), which extended the study to 144 weeks, and MK0518-004-20 (NCT00100048), which extended the study to 240 weeks. Participants who had been randomized to MK0518 in the bas... | HIV Infections Acquired Immunodeficiency Syndrome | null | 10 | arm 1: MK0518 600 mg twice daily arm 2: MK0518 400 mg twice daily arm 3: MK0518 200 mg twice daily arm 4: MK0518 100 mg twice daily arm 5: Placebo to MK0518 twice daily arm 6: MK0518 600 mg + tenofovir + lamivudine arm 7: MK0518 400 mg + tenofovir + lamivudine arm 8: MK0518 200 mg + tenofovir + lamivudine arm 9: MK0518... | [
0,
0,
0,
0,
2,
0,
0,
0,
0,
1
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: MK0518 twice daily for 10 days intervention 2: MK0518 twice daily for 48 weeks intervention 3: efavirenz 600 mg every night at bedtime for 48 weeks intervention 4: tenofovir 300 mg daily for 48 weeks intervention 5: lamivudine 300 mg daily for 48 weeks intervention 6: Placebo to MK0518 twice daily | intervention 1: Comparator: MK0518 monotherapy intervention 2: Comparator: MK0518 combination therapy intervention 3: Comparator: efavirenz intervention 4: Comparator: tenofovir intervention 5: Comparator: lamivudine intervention 6: Placebo monotherapy | 0 | null | 198 | 4 | 0.020202 | 1 | NCT00100048 | 1COMPLETED | 2010-07-01 | 2005-01-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.007884 | |
[
4
] | 1,088 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).
Secondary objectives were:
* to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burde... | The study period per participant was approximatively 128 weeks broken down as follows:
* Screening period up to 4 weeks,
* 108-week double-blind treatment period (approximatively 2 years)\*,
* 16-week post-treatment elimination follow-up period.
'\*' Participants successfully completing the week 108 visit were offere... | Multiple Sclerosis | Multiple Sclerosis Relapsing Remitting Secondary Progressive Progressive Relapsing | null | 3 | arm 1: Teriflunomide 7 mg once daily for 108 weeks arm 2: Teriflunomide 14 mg once daily for 108 weeks arm 3: Placebo (for teriflunomide) once daily for 108 weeks | [
0,
0,
2
] | 2 | [
0,
0
] | intervention 1: Film-coated tablet
Oral administration intervention 2: Film-coated tablet
Oral administration | intervention 1: Teriflunomide intervention 2: Placebo (for teriflunomide) | 21 | Bridgewater | New Jersey | United States | -74.64815 | 40.60079
Vienna | N/A | Austria | 16.37208 | 48.20849
Laval | N/A | Canada | -73.692 | 45.56995
Santiago | N/A | Chile | -70.64827 | -33.45694
Prague | N/A | Czechia | 14.42076 | 50.08804
Hørsholm | N/A | Denmark | 12.50111 | 55.88098
Tallinn | N/A | Estonia | 24.7... | 1,086 | 1 | 0.000921 | 1 | NCT00134563 | 1COMPLETED | 2010-07-01 | 2004-09-01 | Sanofi | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000163 |
[
5
] | 1,032 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA). | This was a 78-week, multicenter, randomized, double-blind, double-treatment period study designed to compare the safety and efficacy of adalimumab and MTX with placebo and MTX in subjects with early RA. Subjects were randomized to receive adalimumab 40 mg every other week (eow) or placebo subcutaneous injections in com... | Rheumatoid Arthritis | Early Rheumatoid Arthritis Tumor Necrosis Factor Optimization | null | 5 | arm 1: Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2 arm 2: Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2 arm 3: Combination therapy with methotrexate (MTX) and ... | [
0,
0,
0,
0,
0
] | 3 | [
2,
0,
2
] | intervention 1: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow) intervention 2: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week. intervention 3: Placebo f... | intervention 1: adalimumab intervention 2: methotrexate intervention 3: placebo | 170 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Birmingham | Alabama | United States | -86.80249 | 33.52066
Huntsville | Alabama | United States | -86.58594 | 34.7304
Mobile | Alabama | United States | -88.04305 | 30.69436
Tuscaloosa | Alabama | United States | -87.56917 | 33.20984
Hemet | California | Unit... | 1,958 | 2 | 0.001021 | 1 | NCT00420927 | 1COMPLETED | 2010-07-01 | 2006-12-01 | Abbott | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00028 |
[
3
] | 13 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma. | The protocol was originally designed as a Simon two stage but after it was determined that the initial 13 patients enrolled did not meet the definition of a 'responder' according to the International Uniform Response Criteria for multiple myeloma the protocol was amended to allow patients who had disease progression at... | Multiple Myeloma | null | 1 | arm 1: Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 t... | [
0
] | 2 | [
0,
0
] | intervention 1: Ruxolitinib was supplied as 5 and 25 mg tablets. intervention 2: Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg. | intervention 1: Ruxolitinib 25 mg intervention 2: Dexamethasone 40 mg | 3 | Highland | California | United States | -117.20865 | 34.12834
Boynton Beach | Florida | United States | -80.06643 | 26.52535
New York | New York | United States | -74.00597 | 40.71427 | 20 | 1 | 0.05 | 1 | NCT00639002 | 1COMPLETED | 2010-07-01 | 2008-03-01 | Incyte Corporation | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.008881 | |
[
3
] | 137 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | false | The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group. | null | Complicated Urinary Tract Infection | null | 2 | arm 1: NXL/104 ceftazidime arm 2: comparator 4 x daily | [
0,
1
] | 2 | [
0,
0
] | intervention 1: 125mg/500mg TID intervention 2: 4 x daily | intervention 1: NXL104/ceftazidime intervention 2: Imipenem/Cilastatin | 59 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Dothan | Alabama | United States | -85.39049 | 31.22323
Mobile | Alabama | United States | -88.04305 | 30.69436
Phoenix | Arizona | United States | -112.07404 | 33.44838
Chula Vista | California | United States | -117.0842 | 32.64005
Escondido | California | U... | 135 | 1 | 0.007407 | 1 | NCT00690378 | 1COMPLETED | 2010-07-01 | 2008-11-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001309 | |
[
4
] | 663 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C. | This is a randomized, double-blind, placebo-controlled Phase III trial with telaprevir in patients with chronic Hepatitis C Virus (HCV), genotype 1, infection who failed prior treatment with standard treatment. Standard treatment is defined as treatment with Peg-INF and RBV. The trial is designed to compare the efficac... | Hepatitis C, Chronic | Hepatitis C, Chronic Telaprevir Peg-IFN-alfa-2a Ribavirin | null | 3 | arm 1: Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses. arm 2: Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 we... | [
0,
0,
0
] | 4 | [
0,
0,
0,
0
] | intervention 1: Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B. intervention 2: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C. intervention 3: Participants will receive ri... | intervention 1: Telaprevir intervention 2: Peg-IFN-alfa-2a intervention 3: Ribavirin intervention 4: Placebo | 91 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Coronado | California | United States | -117.18309 | 32.68589
La Jolla | California | United States | -117.2742 | 32.84727
Los Angeles | California | United States | -118.24368 | 34.05223
San Francisco | California | United States | -122.41942 | 37.77493
Auror... | 1,324 | 2 | 0.001511 | 1 | NCT00703118 | 1COMPLETED | 2010-07-01 | 2008-10-01 | Tibotec BVBA | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000414 |
[
2
] | 47 | NON_RANDOMIZED | null | 0TREATMENT | 0NONE | false | 0ALL | null | Study to determine the maximum tolerated dose of BIBW 2992 when combined with backbone chemotherapies consisting in cisplatin plus paclitaxel or cisplatin plus 5 FU.
The overall safety, the pharmacokinetics and the anti-tumour efficacy will also be assessed. | null | Neoplasms | null | 2 | arm 1: daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel arm 2: daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU | [
0,
0
] | 2 | [
0,
0
] | intervention 1: In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation. intervention 2: low to high dose, daily | intervention 1: BIBW 2992 intervention 2: BIBW 2992 | 3 | Brussels | N/A | Belgium | 4.34878 | 50.85045
Edegem | N/A | Belgium | 4.44504 | 51.15662
Ghent | N/A | Belgium | 3.71667 | 51.05 | 47 | 1 | 0.021277 | 1 | NCT00716417 | 1COMPLETED | 2010-07-01 | 2008-07-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.003766 | |
[
5
] | 491 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to evaluate the efficacy of paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). | This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center), prospective (study following participants forward in time), single arm, and non-comparative study of paliperidone Extended Release(ER) in participants with schizophrenia. The total study duration... | Schizophrenia | Paliperidone R076477 Schizophrenia | null | 1 | arm 1: Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion. | [
0
] | 1 | [
0
] | intervention 1: Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion. | intervention 1: Paliperidone | 20 | Bucheon-Si Gyeonggi-Do | N/A | South Korea | N/A | N/A
Changnyung | N/A | South Korea | N/A | N/A
Chunjoo | N/A | South Korea | N/A | N/A
Daejeon | N/A | South Korea | 127.38493 | 36.34913
Daejun | N/A | South Korea | 126.74156 | 37.58221
Geonggi-Do | N/A | South Korea | N/A | N/A
Gyeonggi-do | N/A | South Korea | 126.... | 491 | 2 | 0.004073 | 1 | NCT00761189 | 1COMPLETED | 2010-07-01 | 2008-02-01 | Janssen Korea, Ltd., Korea | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.001118 |
[
5
] | 270 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after hospital admission), complicated intra-abdominal (in belly) infections and complicated urinary tra... | This is an open-label (all people involved know the identity of the intervention), multi-center (conducted in more than 1 center) study, to evaluate the safety and effectiveness of doripenem in treating Thai participants with nosocomial pneumonia, complicated intra-abdominal and urinary tract infections. The study cons... | Infection Cross Infection Bacterial Infections Pneumonia, Ventilator-Associated Intra-abdominal Infections Urinary Tract Infections | Pneumonia, Ventilator-Associated Intra-abdominal Infections Urinary tract Infections Doripenem Doribax | null | 3 | arm 1: Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days. arm 2: Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated i... | [
0,
0,
0
] | 1 | [
0
] | intervention 1: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days. | intervention 1: Doripenem | 8 | Bangkok | N/A | Thailand | 100.50144 | 13.75398
Chiang Mai | N/A | Thailand | 98.98468 | 18.79038
Chiang Rai | N/A | Thailand | 99.8325 | 19.90858
Chon Buri | N/A | Thailand | 100.98345 | 13.3622
Khon Kaen | N/A | Thailand | 102.833 | 16.44671
Nakhon Ratchasima | N/A | Thailand | 102.10196 | 14.97066
Nakornnayok | N/A ... | 268 | 1 | 0.003731 | 1 | NCT00965848 | 1COMPLETED | 2010-07-01 | 2009-06-01 | Janssen-Cilag Ltd.,Thailand | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000659 |
[
4
] | 240 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | null | Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is mo... | OBJECTIVES:
I. Compare the efficacy of methotrexate vs dactinomycin, as measured by complete response rate, in patients with low-risk gestational trophoblastic neoplasia.
II. Compare the toxicity of these regimens in these patients. III. Determine whether the definition of persistent gestational trophoblastic neoplas... | Good Prognosis Metastatic Gestational Trophoblastic Tumor Hydatidiform Mole Non-Metastatic Gestational Trophoblastic Tumor Uterine Corpus Choriocarcinoma | null | 2 | arm 1: Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment. arm 2: Patients receive dactinomycin IV ov... | [
0,
0
] | 2 | [
2,
0
] | intervention 1: Given IV intervention 2: Given intramuscularly | intervention 1: Dactinomycin intervention 2: Methotrexate | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 214 | 0 | 0 | 0 | NCT00003702 | 1COMPLETED | 2010-07-01 | 1999-06-01 | Gynecologic Oncology Group | 5NETWORK | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 61 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. | OBJECTIVES:
I. Determine the antitumor activity of irofulven in patients with persistent or recurrent platinum-sensitive ovarian epithelial or primary peritoneal cancer.
II. Determine the toxicity of this drug in these patients.
OUTLINE:
Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat ... | Primary Peritoneal Cavity Cancer Recurrent Ovarian Epithelial Cancer | null | 1 | arm 1: Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. | [
0
] | 1 | [
0
] | intervention 1: Given IV | intervention 1: irofulven | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 55 | 0 | 0 | 0 | NCT00053365 | 1COMPLETED | 2010-07-01 | 2003-06-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 26 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growt... | PRIMARY OBJECTIVES:
I. To determine the activity of Gleevec\^trademark (TM) (imatinib mesylate) as measured by progression-free survival at six months.
II. To determine the frequency and severity of adverse effects of Gleevec\^TM in this cohort of patients as assessed by the Common Terminology Criteria of Adverse Eve... | Recurrent Uterine Sarcoma Uterine Carcinosarcoma | null | 1 | arm 1: Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | [
0
] | 2 | [
0,
10
] | intervention 1: Given PO intervention 2: Correlative studies | intervention 1: imatinib mesylate intervention 2: laboratory biomarker analysis | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 23 | 0 | 0 | 0 | NCT00075400 | 1COMPLETED | 2010-07-01 | 2004-01-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 140 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore). | The primary study objective is to compare the efficacy of BBR 2778 to a selection of single agents. Secondary objectives are to compare the safety and tolerability of BBR 2778 to a selection of single agents, and to assess the pharmacokinetic parameters of BBR 2778 in a subset of this patient population. | Lymphoma, Non-Hodgkin | Pixantrone Non-Hodgkins lymphoma | null | 2 | arm 1: Pixantrone (BBR2778) arm 2: To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day) intervention 2: Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day) | intervention 1: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone intervention 2: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab | 99 | Fountain Valley | California | United States | -117.95367 | 33.70918
Los Angeles | California | United States | -118.24368 | 34.05223
Lakeland | Florida | United States | -81.9498 | 28.03947
Chicago | Illinois | United States | -87.65005 | 41.85003
Albuquerque | New Mexico | United States | -106.65114 | 35.08449
Syracu... | 135 | 0 | 0 | 0 | NCT00088530 | 1COMPLETED | 2010-07-01 | 2004-07-01 | CTI BioPharma | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 21 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die. | PRIMARY OBJECTIVES:
I. To determine the antitumor activity of SB-715992 in recurrent and/or metastatic squamous cell carcinoma of the head and neck using objective response rates (partial and complete responses).
SECONDARY OBJECTIVES:
I. To determine the duration of objective response, rate and duration of stable di... | Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and ... | null | 1 | arm 1: Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. | [
0
] | 3 | [
0,
10,
10
] | intervention 1: Given IV intervention 2: Correlative studies intervention 3: Correlative studies | intervention 1: ispinesib intervention 2: laboratory biomarker analysis intervention 3: pharmacological study | 1 | Toronto | Ontario | Canada | -79.39864 | 43.70643 | 20 | 0 | 0 | 0 | NCT00095628 | 1COMPLETED | 2010-07-01 | 2005-01-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 52 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. | PRIMARY OBJECTIVES:
I. To estimate the MTD and describe the DLT of oral lapatinib (GW572016) administered twice daily for 28 days to children with recurrent or refractory malignant brain tumors who are not receiving steroids (Stratum 1) and to describe toxicities in those who are receiving steroids (Stratum 2).
II. T... | Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Ependymoma Recurrent Childhood Giant Cell Glioblastoma Recurrent Childhood Glioblastoma Recurrent Childhood Gliosarcoma Recurrent Childhood Medulloblastoma Recurrent Childhood Oligodendroglioma | null | 1 | arm 1: Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical r... | [
0
] | 6 | [
0,
3,
10,
10,
3,
3
] | intervention 1: Given orally intervention 2: Undergo surgery intervention 3: Correlative studies intervention 4: Correlative studies intervention 5: Correlative studies intervention 6: Correlative studies | intervention 1: lapatinib ditosylate intervention 2: therapeutic conventional surgery intervention 3: laboratory biomarker analysis intervention 4: pharmacological study intervention 5: positron emission tomography intervention 6: magnetic resonance imaging | 1 | Memphis | Tennessee | United States | -90.04898 | 35.14953 | 51 | 0 | 0 | 0 | NCT00095940 | 1COMPLETED | 2010-07-01 | 2004-10-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 74 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | RATIONALE: Gefitinib and everolimus may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving gefitinib together with everolimus may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects, best way to give, and best dose of giving gefitinib with everolimu... | OBJECTIVES:
Primary
* Determine the maximum tolerated dose of everolimus when administered with gefitinib in patients with stage IIIB or IV or recurrent non-small cell lung cancer. (Phase I)
* Determine the efficacy of this regimen in these patients. (Phase II)
Secondary
* Assess the pharmacokinetics of everolimus,... | Lung Cancer | recurrent non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer | null | 1 | arm 1: Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progressio... | [
0
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: everolimus intervention 2: gefitinib | 1 | New York | New York | United States | -74.00597 | 40.71427 | 74 | 0 | 0 | 0 | NCT00096486 | 1COMPLETED | 2010-07-01 | 2004-05-01 | Memorial Sloan Kettering Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 55 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying ho... | OBJECTIVES:
* Determine the antitumor activity of paclitaxel and carboplatin in patients with persistent or recurrent stage III or IV uterine carcinosarcoma.
* Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: This is a non-randomized, multicenter study.
Patients receive paclita... | Sarcoma | recurrent uterine sarcoma stage III uterine sarcoma stage IV uterine sarcoma uterine carcinosarcoma | null | 1 | arm 1: Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy | [
0
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: carboplatin intervention 2: paclitaxel | 110 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Los Angeles | California | United States | -118.24368 | 34.05223
New Britain | Connecticut | United States | -72.77954 | 41.66121
Lewes | Delaware | United States | -75.13935 | 38.77456
Newark | Delaware | United States | -75.74966 | 39.68372
Jacksonville | Fl... | 46 | 0 | 0 | 0 | NCT00112489 | 1COMPLETED | 2010-07-01 | 2005-05-01 | Gynecologic Oncology Group | 5NETWORK | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 28 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder. | An expanding body of clinical experience and controlled trials has established the efficacy of serotonin selective reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine, for the treatment of social anxiety disorder, with paroxetine, sertraline and venlafaxine extended-releas... | Anxiety Disorder | social anxiety disorder social phobia duloxetine serotonin norepinephrine reuptake inhibitor SNRI double blind | null | 3 | arm 1: In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine. arm 2: In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine. arm 3: In Phase 1 all participants entered an open trial. | [
2,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: 60 mg duloxetine 1x per day intervention 2: 60 mg duloxetine 1x per day + 60mg duloxetine 1x per day intervention 3: 60mg placebo 1x per day | intervention 1: Duloxetine intervention 2: Duloxetine intervention 3: Placebo | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 28 | 0 | 0 | 0 | NCT00114127 | 1COMPLETED | 2010-07-01 | 2004-06-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 28 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer. Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping ... | OBJECTIVES:
I. Determine the antitumor activity of gemcitabine and docetaxel in patients with recurrent or persistent uterine carcinosarcoma.
II. Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: This is a non-randomized, multicenter study. Patients receive gemcitabine IV over 3... | Recurrent Uterine Corpus Sarcoma Uterine Carcinosarcoma | null | 1 | arm 1: Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. | [
0
] | 2 | [
0,
0
] | intervention 1: Given IV intervention 2: Given IV | intervention 1: Gemcitabine Hydrochloride intervention 2: Docetaxel | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 24 | 0 | 0 | 0 | NCT00114218 | 1COMPLETED | 2010-07-01 | 2005-03-01 | Gynecologic Oncology Group | 5NETWORK | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 95 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder. | Comorbid alcohol/substance use disorder (SUD) in people with schizophrenia is a major concern, both in view of the high frequency of SUD among patients with schizophrenia and the difficulty in managing such patients. Though antipsychotic medications are effective in reducing symptoms and impairment in persons with schi... | Schizophrenia Psychotic Disorders Substance Abuse Alcohol Abuse | Risperidone Schizophrenia Substance Use Disorder Alcohol Use Disorder Treatment Schizoaffective Disorder | null | 2 | arm 1: Risperidone Long Acting; aka Risperdal Consta; injectable form arm 2: Oral Risperidone; aka Risperdal; oral form | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Dose 25.00, 37.50 or 50.00 mg q two weeks intervention 2: 0.50-6.00 mg oral risperidone daily | intervention 1: Risperidone Long Acting intervention 2: oral risperidone | 8 | Miami | Florida | United States | -80.19366 | 25.77427
Kansas City | Missouri | United States | -94.57857 | 39.09973
St Louis | Missouri | United States | -90.19789 | 38.62727
Lebanon | New Hampshire | United States | -72.25176 | 43.64229
Manchester | New Hampshire | United States | -71.45479 | 42.99564
Nashua | New Ha... | 95 | 0 | 0 | 0 | NCT00130923 | 1COMPLETED | 2010-07-01 | 2005-09-01 | Dartmouth-Hitchcock Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 40 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer. Patients with advanced or recurrent head and neck cancer, which is untreatable by surgery or radiation therapy are eligible for this study. Stand... | Approximately 28,900 patients will be diagnosed with squamous cell cancers of the oral cavity and pharynx in the year 2002. Of these, an estimated 7,400 patients will present with metastases or develop recurrent disease, which is not amenable to surgery or radiation therapy. Palliative chemotherapy is thus the only tre... | Head and Neck Cancer | Squamous cell cancer of the oral cavity and pharynx | null | 1 | arm 1: Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, \&15) | [
0
] | 2 | [
0,
0
] | intervention 1: Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no ev... | intervention 1: Docetaxel intervention 2: Capecitabine | 1 | Ann Arbor | Michigan | United States | -83.74088 | 42.27756 | 38 | 0 | 0 | 0 | NCT00148122 | 1COMPLETED | 2010-07-01 | 2002-11-01 | University of Michigan Rogel Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 16 | NA | SINGLE_GROUP | 2DIAGNOSTIC | 0NONE | false | 0ALL | true | The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this combined modality approach in patients with mesothelioma; to evaluate cisplatin effects by de... | OBJECTIVES:
Primary
* To determine the feasibility of administering adjuvant cisplatin plus Alimta to patients undergoing surgery with hyperthermic cisplatin.
Secondary
* To determine the morbidity and mortality of this treatment protocol
* To determine time to tumor recurrence and patient survival
* To evaluate th... | Pleural Mesothelioma Malignant Pleural Mesothelioma | pleurectomy decortication cisplatin ALIMTA | null | 1 | arm 1: Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimt... | [
0
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: Cisplatin intervention 2: Sodium Thiosulfate intervention 3: ALIMTA | 2 | Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston | Massachusetts | United States | -71.05977 | 42.35843 | 16 | 0 | 0 | 0 | NCT00165503 | 6TERMINATED | 2010-07-01 | 2004-04-01 | Dana-Farber Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 12 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation. This research study involves treatment with an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of this study is to assess the effectiveness of t... | null | Carcinoma of the Head and Neck | null | 1 | arm 1: On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days. | [
0
] | 2 | [
0,
0
] | intervention 1: Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion. intervention 2: Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks. | intervention 1: Taxotere intervention 2: Oxaliplatin | 1 | Los Angeles | California | United States | -118.24368 | 34.05223 | 12 | 0 | 0 | 0 | NCT00184028 | 6TERMINATED | 2010-07-01 | 2004-09-01 | University of Southern California | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 36 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin, oxaliplatin (FOLFOX6), bevacizumab, and cetuximab in patients with metastatic colorectal cancer. FOLFOX6 has proven to be a safe and effective regimen in first line treatment of advanced colorectal cancer. The role of epidermal ... | All patients received cetuximab: 400 mg/m2 (first cycle only) administered intravenously (IV) on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8. Day 1 cetuximab was immediately followed by bevacizumab 5 mg/kg IV, oxaliplatin 85 mg/m2 IV, and 5-fluorouracil 400 mg/m2 IV bolus, fo... | Colon Cancer | Colon Cancer | null | 1 | arm 1: Bevacizumab 5 mg/kg IV
Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
Leucovorin 350 m... | [
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: 5 mg/kg IV intervention 2: 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8 intervention 3: 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient) intervention 4:... | intervention 1: Bevacizumab intervention 2: Cetuximab intervention 3: 5-fluorouracil intervention 4: Leucovorin intervention 5: Oxaliplatin | 10 | Evansville | Indiana | United States | -87.55585 | 37.97476
Louisville | Kentucky | United States | -85.75941 | 38.25424
Portland | Maine | United States | -70.2589 | 43.65737
Bethesda | Maryland | United States | -77.10026 | 38.98067
Jackson | Mississippi | United States | -90.18481 | 32.29876
Chesterfield | Missouri ... | 36 | 0 | 0 | 0 | NCT00193219 | 1COMPLETED | 2010-07-01 | 2005-07-01 | SCRI Development Innovations, LLC | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 123 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Modafinil, a medication that enhances mood, increases energy, and improves concentration, may be useful in preventing relapse among individuals with cocaine addiction. This study will evaluate the effectiveness of ... | The development of a medication to treat cocaine addiction specifically by lessening withdrawal symptoms has been a primary focus of research. Common cocaine withdrawal symptoms include depression, lack of energy, and poor concentration. Modafinil, a central nervous system stimulant, is a medication that can speed up p... | Cocaine Dependence | Cocaine Dependence | null | 3 | arm 1: 200mg Modafinil arm 2: 400mg Modafinil arm 3: Matching Placebo | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: 200mg Modafinil intervention 2: 400mg Modafinil intervention 3: Matching Placebo | intervention 1: Modafinil intervention 2: Modafinil intervention 3: Matching Placebo | 1 | Charleston | South Carolina | United States | -79.93275 | 32.77632 | 123 | 0 | 0 | 0 | NCT00218387 | 1COMPLETED | 2010-07-01 | 2004-04-01 | Medical University of South Carolina | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3,
4
] | 34 | RANDOMIZED | CROSSOVER | 1PREVENTION | 0NONE | false | 0ALL | null | The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors. | null | Hemophilia A With Inhibitors | null | 2 | arm 1: Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug arm 2: Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug | [
5,
5
] | 1 | [
0
] | intervention 1: FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months
FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months | intervention 1: activated prothrombin complex concentrate (FEIBA) | 1 | New Orleans | Louisiana | United States | -90.07507 | 29.95465 | 91 | 0 | 0 | 0 | NCT00221195 | 1COMPLETED | 2010-07-01 | 2003-06-01 | Tulane University School of Medicine | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 48 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | false | Our aim is to compare the safety and efficacy of 2 different empiric levothyroxine dose adjustment recommendations to be made at the first confirmation of pregnancy in women with a history of hypothyroidism. Subjects will be women with a prior diagnosis of hypothyroidism who are taking thyroid hormone replacement and w... | Our aim is to compare the safety and efficacy of 2 different empiric levothyroxine dose adjustment recommendations to be made at the first confirmation of pregnancy in women with a history of hypothyroidism. Subjects will be women with a prior diagnosis of hypothyroidism who are taking thyroid hormone replacement and w... | Pregnancy Hypothyroidism | pregnancy hypothyroidism levothyroxine | null | 2 | arm 1: Patients will increase their current levothyroxine dose by 2 extra tablets per week (\~29% increase) arm 2: Patients will increase their levothyroxine dosage by 3 extra tablets per week (\~43%). | [
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts. intervention 2: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week intervention 3: patients will increase levothy... | intervention 1: Anticipatory dose increase of levothyroxine intervention 2: levothyroxine intervention 3: levothyroxine | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 48 | 0 | 0 | 0 | NCT00230802 | 1COMPLETED | 2010-07-01 | 2005-07-01 | Brigham and Women's Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 56 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with advanced or recurrent uterine cancer. | PRIMARY OBJECTIVES:
I. Determine the objective response rate in patients with advanced or recurrent uterine cancer treated with sorafenib.
II. Determine the toxic effects of this drug in these patients.
SECONDARY OBJECTIVES:
I. Determine progression-free survival of patients treated with this drug.
OUTLINE: This i... | Recurrent Uterine Sarcoma Stage III Uterine Sarcoma Stage IV Uterine Sarcoma Uterine Carcinosarcoma | null | 1 | arm 1: Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | [
0
] | 1 | [
0
] | intervention 1: Given orally | intervention 1: sorafenib tosylate | 7 | Duarte | California | United States | -117.97729 | 34.13945
Los Angeles | California | United States | -118.24368 | 34.05223
Decatur | Illinois | United States | -88.9548 | 39.84031
Springfield | Illinois | United States | -89.64371 | 39.80172
Hamilton | Ontario | Canada | -79.84963 | 43.25011
Kingston | Ontario | Cana... | 56 | 0 | 0 | 0 | NCT00238121 | 1COMPLETED | 2010-07-01 | 2005-02-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 60 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with t... | null | Breast Neoplasms | Breast Cancer Metastatic | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdr... | intervention 1: SU011248/Trastuzumab | 27 | Montgomery | Alabama | United States | -86.29997 | 32.36681
Newark | Delaware | United States | -75.74966 | 39.68372
Newark | Delaware | United States | -75.74966 | 39.68372
Wilmington | Delaware | United States | -75.54659 | 39.74595
Fort Lauderdale | Florida | United States | -80.14338 | 26.12231
Harvey | Illinois | ... | 60 | 0 | 0 | 0 | NCT00243503 | 1COMPLETED | 2010-07-01 | 2006-02-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3,
4
] | 159 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | null | This is a prospective, randomized controlled clinical trial to evaluate the efficacy and safety of intravenous patient controlled analgesia (IVPCA) in patients following major intracranial surgery (e.g. brain tumors, vascular surgery). We will compare pain, opioid consumption, costs, sedation level, length of hospital ... | null | Intracranial Surgery | null | 4 | arm 1: None arm 2: None arm 3: None arm 4: None | [
0,
1,
0,
1
] | 2 | [
0,
0
] | intervention 1: PCA fentanyl 0.5 ug/kg with a dosing interval ("lockout") of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug... | intervention 1: PCA fentanyl intervention 2: PRN fentanyl | 1 | Baltimore | Maryland | United States | -76.61219 | 39.29038 | 129 | 0 | 0 | 0 | NCT00286221 | 1COMPLETED | 2010-07-01 | 2006-03-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 676 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an intern... | null | Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 2 | [
0,
0
] | intervention 1: VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5. intervention 2: rituximab once a week on Days 1,... | intervention 1: Bortezomib + Rituximab intervention 2: Rituximab | 206 | Opelika | Alabama | United States | -85.37828 | 32.64541
Alhambra | California | United States | -118.12701 | 34.09529
Bakersfield | California | United States | -119.01871 | 35.37329
Burbank | California | United States | -118.30897 | 34.18084
Fullerton | California | United States | -117.92534 | 33.87029
La Verne | C... | 673 | 0 | 0 | 0 | NCT00312845 | 1COMPLETED | 2010-07-01 | 2006-03-01 | Millennium Pharmaceuticals, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 42 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT. | null | Gaucher Disease Type 1 | enzyme replacement therapy Type 1 Gaucher Disease miglustat | null | 1 | arm 1: Oral administration of miglustat 100 mg t.i.d. for a period of 2 years | [
0
] | 1 | [
0
] | intervention 1: Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.) | intervention 1: Miglustat | 0 | null | 42 | 0 | 0 | 0 | NCT00319046 | 1COMPLETED | 2010-07-01 | 2006-02-01 | Actelion | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 1,142 | RANDOMIZED | PARALLEL | 1PREVENTION | 3TRIPLE | false | 0ALL | true | The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD). | BACKGROUND:
The prevalence, morbidity, mortality, and treatment cost of COPD are high and increasing. COPD is the sixth leading cause of death worldwide and is the only condition in the top 10 causes of death that has an increasing prevalence and mortality. The cost of health care for patients with COPD in the U.S. is... | Pulmonary Disease, Chronic Obstructive | null | 2 | arm 1: Macrolide Antibiotic (Azithromycin) arm 2: Inactive | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Azithromycin (daily capsule, 250 mg for 12 months) intervention 2: Placebo taken on a daily basis | intervention 1: Macrolide Antibiotic (Azithromycin) intervention 2: Placebo | 10 | Birmingham | Alabama | United States | -86.80249 | 33.52066
San Francisco | California | United States | -122.41942 | 37.77493
Torrance | California | United States | -118.34063 | 33.83585
Denver | Colorado | United States | -104.9847 | 39.73915
Baltimore | Maryland | United States | -76.61219 | 39.29038
Boston | Massa... | 1,142 | 0 | 0 | 0 | NCT00325897 | 1COMPLETED | 2010-07-01 | 2006-03-01 | University of Minnesota | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 68 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This study was an early-phase trial arranged into two phases. The Phase I portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Phase II was intended to assess the activity, safe... | null | Non-Hodgkin's Lymphoma Hodgkin's Disease | null | 2 | arm 1: Phase 1 dose escalation without and with GCSF support arm 2: Phase 2 fixed dose based on Phase I findings stratified by NHL type | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops. intervention 2: Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings. | intervention 1: SB-743921 intervention 2: SB-743921 | 8 | Hackensack | New Jersey | United States | -74.04347 | 40.88593
New York | New York | United States | -74.00597 | 40.71427
New York | New York | United States | -74.00597 | 40.71427
New York | New York | United States | -74.00597 | 40.71427
Chapel Hill | North Carolina | United States | -79.05584 | 35.9132
Nashville | T... | 63 | 0 | 0 | 0 | NCT00343564 | 1COMPLETED | 2010-07-01 | 2006-04-01 | Cytokinetics | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 420 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | true | Emergency intubation of patients in intensive care is a high-risk endeavour. For many decades, succinylcholine has been the neuromuscular blocking agent of choice. However, succinylcholine may have life-threatening side effects and is contraindicated in a variety of diseases relevant in intensive care. The nondepolariz... | Objective: to compare succinylcholine and rocuronium with regard to 1) quality of intubating conditions, 2) length of the intubating sequence, 3) failed intubating attempts, 4) hemodynamic sequelae of intubation, and 5) desaturations.
Design: prospective, randomized, single-blind study. Setting: Intensive care units o... | Intubation | intubation intensive care neuromuscular depolarizing agents neuromuscular nondepolarizing agents neuromuscular blocking agents | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 2 | [
0,
0
] | intervention 1: 1mg/kg iv intervention 2: 0.6mg/kg iv | intervention 1: Succinylcholine intervention 2: Rocuronium | 1 | Basel | Canton of Basel-City | Switzerland | 7.57327 | 47.55839 | 420 | 0 | 0 | 0 | NCT00355368 | 1COMPLETED | 2010-07-01 | 2006-08-01 | University Hospital, Basel, Switzerland | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 12 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory acute myeloid leukemia or older patients with newly diagnosed acute myeloid leukemia. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the... | PRIMARY OBJECTIVES:
I. Evaluate the response rate (complete response and partial response) in patients with acute myeloid leukemia treated with PXD101.
SECONDARY OBJECTIVES:
I. Evaluate the overall survival of these patients. II. Evaluate the duration of response in these patients. III. Evaluate the toxicity of this... | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Ad... | null | 1 | arm 1: Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity. | [
0
] | 2 | [
0,
10
] | intervention 1: Given IV intervention 2: Correlative studies | intervention 1: belinostat intervention 2: laboratory biomarker analysis | 1 | Duarte | California | United States | -117.97729 | 34.13945 | 12 | 0 | 0 | 0 | NCT00357032 | 1COMPLETED | 2010-07-01 | 2006-05-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 81 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or ... | PRIMARY OBJECTIVE:
I. To compare the efficacy and tolerability of sequential vs concurrent docetaxel and bortezomib in patients with previously treated, progressive or recurrent, advanced non-small cell lung cancer (NSCLC).
SECOND OBJECTIVES:
I. To compare time to progression in patients with previously treated NSCL... | Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer | null | 2 | arm 1: Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8. arm 2: Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8. | [
0,
0
] | 6 | [
0,
0,
10,
10,
10,
10
] | intervention 1: Given IV intervention 2: Given IV intervention 3: correlative study intervention 4: correlative study intervention 5: correlative study intervention 6: correlative study | intervention 1: docetaxel intervention 2: bortezomib intervention 3: laboratory biomarker analysis intervention 4: immunoenzyme technique intervention 5: immunohistochemistry staining method intervention 6: pharmacological study | 1 | Duarte | California | United States | -117.97729 | 34.13945 | 81 | 0 | 0 | 0 | NCT00362882 | 1COMPLETED | 2010-07-01 | 2006-07-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 302 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 2MALE | true | The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management). | null | Neoplasms, Prostate | Dutasteride Prostate Cancer Expectant management REDEEM | null | 2 | arm 1: Dutasteride 0.5mg arm 2: Matching placebo | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Dutasteride 0.5mg intervention 2: Matching placebo | intervention 1: Dutasteride intervention 2: Matching placebo | 82 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Beverly Hills | California | United States | -118.40036 | 34.07362
Laguna Hills | California | United States | -117.71283 | 33.61252
Mission Hills | California | United States | -120.43683 | 34.68609
Modesto | California | United States | -120.99688 | 37.639... | 302 | 0 | 0 | 0 | NCT00363311 | 1COMPLETED | 2010-07-01 | 2006-07-01 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 48 | RANDOMIZED | PARALLEL | 1PREVENTION | 1SINGLE | true | 1FEMALE | false | We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adol... | Pregnancy prevention is an important aspect of adolescent healthcare. Adherence to a chosen contraception method is essential to its success. Adolescents are notoriously poor at complying with oral contraceptives (OCs), with continuation rates at one year as low as 12% (1). In those patients who continue their contrace... | Contraception Desired | Contraception Adolescents Contraceptive vaginal ring Quick start | null | 2 | arm 1: Start contraceptive method (NuvaRing) day of enrollment arm 2: Start contraceptive method (NuvaRing) after next menses (per package insert) | [
0,
1
] | 1 | [
0
] | intervention 1: Initiation of NuvaRing for contraception | intervention 1: NuvaRing | 1 | Richmond | Virginia | United States | -77.46026 | 37.55376 | 48 | 0 | 0 | 0 | NCT00369967 | 6TERMINATED | 2010-07-01 | 2007-02-01 | Virginia Commonwealth University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 1,055 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID and F 10 mcg BID in adults at least 40 years ... | null | Chronic Obstructive Pulmonary Disease (COPD) | null | 5 | arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None | [
0,
0,
0,
1,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks intervention 2: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks intervention 3: MF 400 mcg via metered dose inhaler twice daily for 52 weeks intervention 4: Formoterol 10 mcg via metered dose inhaler twic... | intervention 1: Mometasone furoate/formoterol (MF/F) combination intervention 2: Mometasone furoate/formoterol (MF/F) combination intervention 3: Mometasone furoate MDI (MF MDI) intervention 4: Formoterol MDI intervention 5: Placebo | 0 | null | 1,055 | 0 | 0 | 0 | NCT00383435 | 1COMPLETED | 2010-07-01 | 2006-10-01 | Organon and Co | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 1,196 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID and F 10 mcg BID in adults at least 40 years ... | null | Chronic Obstructive Pulmonary Disease (COPD) | null | 5 | arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None | [
0,
0,
0,
1,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks intervention 2: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks intervention 3: MF 400 mcg via metered dose inhaler twice daily for 52 weeks intervention 4: Formoterol 10 mcg via metered dose inhaler twic... | intervention 1: Mometasone furoate/formoterol (MF/F) combination intervention 2: Mometasone furoate/formoterol (MF/F) combination intervention 3: Mometasone furoate MDI (MF MDI) intervention 4: Formoterol MDI intervention 5: Placebo | 0 | null | 1,196 | 0 | 0 | 0 | NCT00383721 | 1COMPLETED | 2010-07-01 | 2006-09-01 | Organon and Co | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 616 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis. | null | Idiopathic Pulmonary Fibrosis | BUILD 3 Idiopathic Pulmonary Fibrosis Tracleer Interstitial Lung Disease bosentan Actelion | null | 2 | arm 1: Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg b.i.d. (if body weight \< 40 kg) arm 2: Subjects receive placebo matching the bosentan treatment regimen | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg) intervention 2: Placebo matching bosentan 62.5 mg tablets and 125 mg tablets | intervention 1: Bosentan intervention 2: Placebo | 0 | null | 615 | 0 | 0 | 0 | NCT00391443 | 1COMPLETED | 2010-07-01 | 2007-02-01 | Actelion | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 31 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer. | null | Cancer | null | 6 | arm 1: LY2603618 40 milligrams per square meter (mg/m\^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed. arm 2: Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m\^2 \[4.5-hour infusion\]), the LY2603618 40 mg/m\^2 d... | [
0,
0,
0,
0,
0,
0
] | 7 | [
0,
0,
0,
0,
0,
0,
0
] | intervention 1: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2. intervention 2: 70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. intervention... | intervention 1: IC83/LY2603618 intervention 2: IC83/LY2603618 intervention 3: IC83/LY2603618 intervention 4: IC83/LY2603618 intervention 5: IC83/LY2603618 intervention 6: pemetrexed intervention 7: pemetrexed | 1 | Scottsdale | Arizona | United States | -111.89903 | 33.50921 | 31 | 0 | 0 | 0 | NCT00415636 | 1COMPLETED | 2010-07-01 | 2007-01-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 48 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome. The efficacy of Aliskiren was compared to Amlodipine. | null | High Blood Pressure Metabolic Syndrome Insulin Resistance Endothelial Dysfunction | High Blood pressure Hypertension metabolic syndrome insulin resistance endothelial dysfunction pre-diabetic amlodipine, aliskiren, IGT, IFG, MBF | null | 2 | arm 1: Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed. arm 2: Eligible participants received ... | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Aliskiren 300 mg tablets taken orally once daily intervention 2: Amlodipine 5 mg capsule taken orally once daily intervention 3: Placebo Aliskiren taken orally once daily. intervention 4: Placebo Amlodipine taken orally once daily | intervention 1: Aliskiren intervention 2: Amlodipine intervention 3: Placebo Aliskiren intervention 4: Placebo Amlodipine | 1 | Santa Monica | California | United States | -118.49138 | 34.01949 | 48 | 0 | 0 | 0 | NCT00417170 | 1COMPLETED | 2010-07-01 | 2007-10-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 1 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | true | Primary Objective:
* To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing neoadjuvant and/or adjuvant chemotherapy for primary invasive breast cancer by documenting persistence or resumption of regular menses.
Secondary Objectives:
* To determ... | Goserelin is designed to block hormones that can regulate your menstruation by affecting the pituitary gland (part of brain).
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to one of two treatment groups. You will either be assigned to receive goser... | Breast Cancer | Breast Cancer Chemotherapy Ovarian Function Goserelin Zoladex Ovary function Fertility Early Menopause | null | 2 | arm 1: 3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy. arm 2: None | [
0,
4
] | 1 | [
0
] | intervention 1: 3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose. | intervention 1: Goserelin | 2 | Houston | Texas | United States | -95.36327 | 29.76328
Tokyo | N/A | Japan | 139.69171 | 35.6895 | 1 | 0 | 0 | 0 | NCT00429403 | 6TERMINATED | 2010-07-01 | 2006-08-01 | M.D. Anderson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 515 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by randomization to either a simplification regimen of... | Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infec... | Infection, Human Immunodeficiency Virus I HIV Infection | NORVIR ARIES EPZICOM REYATAZ HIV simplification Antiretroviral-naive | null | 2 | arm 1: Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen. arm 2: Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD fo... | [
5,
5
] | 2 | [
0,
0
] | intervention 1: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen intervention 2: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks follo... | intervention 1: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r) intervention 2: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) | 72 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Long Beach | California | United States | -118.18923 | 33.76696
Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
Newport Beach | California | United States | -117.92895 | 33.61891
O... | 1,303 | 0 | 0 | 0 | NCT00440947 | 1COMPLETED | 2010-07-01 | 2007-03-01 | ViiV Healthcare | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 333 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial grow... | Proliferative diabetic retinopathy (PDR) is manifested in retinal neovascularization at the disc (NVD) or elsewhere (NVE). Vitreous hemorrhage or tractional detachment from PDR is a leading cause of severe visual loss and new onset blindness. Without intervention, 60 percent of individuals with diabetic retinopathy wil... | Proliferative Diabetic Retinopathy Diabetic Macular Edema | Diabetic Retinopathy Diabetic Macular Edema Lucentis Ranibizumab Triamcinolone Panretinal Photocoagulation Combination Therapy pdr | null | 3 | arm 1: Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups. arm 2: Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 ... | [
0,
0,
1
] | 4 | [
0,
0,
5,
3
] | intervention 1: Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks intervention 2: Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks intervention 3: Sham injection at baseline and 4 weeks intervention 4: Focal/grid laser for diabetic macular edema was per... | intervention 1: Ranibizumab intervention 2: Triamcinolone Acetonide intervention 3: Sham injection intervention 4: Focal/grid laser | 56 | Artesia | California | United States | -118.08312 | 33.86585
Beverly Hills | California | United States | -118.40036 | 34.07362
Irvine | California | United States | -117.82311 | 33.66946
Loma Linda | California | United States | -117.26115 | 34.04835
Palm Springs | California | United States | -116.54529 | 33.8303
San... | 364 | 0 | 0 | 0 | NCT00445003 | 1COMPLETED | 2010-07-01 | 2007-03-01 | Jaeb Center for Health Research | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 550 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction. | null | Arthritis, Rheumatoid | Rheumatoid Arthritis Arthritis | null | 3 | arm 1: None arm 2: None arm 3: None | [
0,
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: 10 mg twice weekly, subcutaneous injection for 52 weeks intervention 2: 25 mg, twice weekly, subcutaneous injection for 52 weeks intervention 3: up to 8 mg per week, oral dosing for 52 weeks | intervention 1: Etanercept intervention 2: Etanercept intervention 3: Methotrexate | 41 | Nagoya | Aichi-ken | Japan | 136.90641 | 35.18147
Nagoya | Aichi-ken | Japan | 136.90641 | 35.18147
Goshogawara | Aomori | Japan | 140.44139 | 40.80444
Asahi | Chiba | Japan | 140.65 | 35.71667
Matsuyama | Ehime | Japan | 132.76574 | 33.83916
Fukui-shi | Fukui | Japan | 136.22257 | 36.06443
Fukuoka | Fukuoka | Japan | ... | 550 | 0 | 0 | 0 | NCT00445770 | 1COMPLETED | 2010-07-01 | 2006-07-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 1 | null | null | 0TREATMENT | 0NONE | false | 0ALL | false | RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infus... | OBJECTIVES:
Primary
* Determine the effect of haploidentical donor CD34+ purified peripheral blood stem cells and donor natural killer (NK) cells on the risk of developing grades III-IV acute graft-vs-host disease in patients with leukemia or other hematologic diseases.
Secondary
* Determine the risk for mortality ... | Graft Versus Host Disease Leukemia Myelodysplastic Syndromes | graft versus host disease adult acute lymphoblastic leukemia in remission recurrent adult acute lymphoblastic leukemia childhood acute lymphoblastic leukemia in remission recurrent childhood acute lymphoblastic leukemia adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia in remissio... | null | 0 | null | null | 11 | [
2,
2,
0,
0,
0,
6,
10,
10,
3,
3,
4
] | intervention 1: None intervention 2: None intervention 3: None intervention 4: None intervention 5: None intervention 6: None intervention 7: None intervention 8: None intervention 9: None intervention 10: None intervention 11: None | intervention 1: muromonab-CD3 intervention 2: natural killer cell therapy intervention 3: fludarabine phosphate intervention 4: methotrexate intervention 5: thiotepa intervention 6: gene expression analysis intervention 7: flow cytometry intervention 8: immunologic technique intervention 9: allogeneic hematopoietic ste... | 2 | Seattle | Washington | United States | -122.33207 | 47.60621
Seattle | Washington | United States | -122.33207 | 47.60621 | 1 | 0 | 0 | 0 | NCT00450983 | 6TERMINATED | 2010-07-01 | 2006-12-01 | Fred Hutchinson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 158 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This study will assess the safety and efficacy of Xeloda, given in combination with standard chemotherapy regimens, for the first-line treatment of advanced and/or metastatic gastric cancer. All patients will receive Xeloda in combination with one of 4 standard chemotherapy regimens; the dose of Xeloda will be from 625... | null | Gastric Cancer | null | 4 | arm 1: Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks. arm 2: Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capeci... | [
0,
0,
0,
0
] | 8 | [
0,
0,
0,
0,
0,
0,
0,
0
] | intervention 1: 80 mg/m2/day, intravenous (IV), every 3 weeks intervention 2: 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle intervention 3: 50 mg/m2/day, IV, every 3 weeks intervention 4: 60 mg/m2/day, IV, every 3 weeks intervention 5: 625 mg/m2, oral, twice daily per 3-week cycle... | intervention 1: Cisplatin intervention 2: Capecitabine intervention 3: Epirubicin intervention 4: Cisplatin intervention 5: Capecitabine intervention 6: Oxaliplatin intervention 7: Docetaxel intervention 8: Capecitabine | 51 | Alcoy | Alicante | Spain | -0.47432 | 38.70545
Ávila | Avila | Spain | -4.69951 | 40.65724
Palma de Mallorca | Balearic Islands | Spain | 2.65024 | 39.56939
Palma de Mallorca | Balearic Islands | Spain | 2.65024 | 39.56939
Barcelona | Barcelona | Spain | 2.15899 | 41.38879
Burgos | Burgos | Spain | -3.70184 | 42.34106
... | 158 | 0 | 0 | 0 | NCT00454636 | 1COMPLETED | 2010-07-01 | 2007-03-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 24 | null | null | 0TREATMENT | 0NONE | false | 1FEMALE | true | RATIONALE: Progesterone can cause the growth of ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer. Hormone therapy using mifepristone may fight ovarian epithelial cancer and primary peritoneal cancer by lowering the amount of progesterone the body makes.
PURPOSE: This phase II trial is st... | OBJECTIVES:
Primary
* Determine the antitumor activity of mifepristone in patients with recurrent or persistent ovarian epithelial, primary peritoneal, or fallopian tube carcinoma.
* Determine the toxicity of this drug in these patients.
Secondary
* Determine the duration of progression-free survival and overall su... | Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer | recurrent ovarian epithelial cancer primary peritoneal cavity cancer fallopian tube cancer | null | 1 | arm 1: Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy. | [
0
] | 1 | [
0
] | intervention 1: None | intervention 1: mifepristone | 22 | Los Angeles | California | United States | -118.24368 | 34.05223
Hartford | Connecticut | United States | -72.68509 | 41.76371
New Britain | Connecticut | United States | -72.77954 | 41.66121
Hinsdale | Illinois | United States | -87.93701 | 41.80086
Baton Rouge | Louisiana | United States | -91.18747 | 30.44332
Portla... | 22 | 0 | 0 | 0 | NCT00459290 | 1COMPLETED | 2010-07-01 | 2007-05-01 | Gynecologic Oncology Group | 5NETWORK | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 50 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: The general results of combining irinotecan and platin-based chemotherapies have been very encouraging. As the toxicity profile associated with carboplatin is preferable over cisplatin it is our expectation that patients and physicians would prefer to use this combination if it is equally or more efficacious... | OBJECTIVES:
Primary
* To examine the anti-tumor efficacy of the combination of Irinotecan (CPT-11) and Carboplatin as first-line therapy as assessed by response rate in patients with chemo-naïve extensive stage small cell lung cancer.
Secondary
* Determine the safety, tolerability, and feasibility of this regimen i... | Lung Cancer | extensive stage small cell lung cancer | null | 1 | arm 1: Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded ... | [
0
] | 2 | [
0,
0
] | intervention 1: Carboplatin dosage calculation to be given on day 1, every 21 days:
Carboplatin (mg) = (AUC of 5) x (GFR + 25)
\*up to 6 cycles at physician's discretion intervention 2: 50 mg/m2 IV on days 1 and 8 every 21 days
Should be infused IV over 30- 90 minutes. | intervention 1: Carboplatin intervention 2: irinotecan hydrochloride | 8 | Owensboro | Kentucky | United States | -87.11333 | 37.77422
Chattanooga | Tennessee | United States | -85.30968 | 35.04563
Jackson | Tennessee | United States | -88.81395 | 35.61452
Knoxville | Tennessee | United States | -83.92074 | 35.96064
Nashville | Tennessee | United States | -86.78444 | 36.16589
Nashville | Tenn... | 50 | 0 | 0 | 0 | NCT00469898 | 1COMPLETED | 2010-07-01 | 2003-12-01 | Vanderbilt-Ingram Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 514 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression. | 1. Dose range and administration mode: Oral Olanzapine 5mg - 20mg/day
2. Duration:
1. Screening phase is 2-28 days.
2. Double-blind treatment phase is 6 weeks
3. Open-label extension phase is 18 weeks | Depression, Bipolar | null | 3 | arm 1: During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tol... | [
0,
2,
0
] | 2 | [
0,
0
] | intervention 1: 5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period). intervention 2: placebo tablets, oral, once daily at bedtime, 6 weeks | intervention 1: Olanzapine intervention 2: Placebo | 16 | Beijing | N/A | China | 116.39723 | 39.9075
Changsha | N/A | China | 112.97087 | 28.19874
Chengdu | N/A | China | 104.06667 | 30.66667
Guangzhou | N/A | China | 113.25 | 23.11667
Hangzhou | N/A | China | 120.16142 | 30.29365
Harbin | N/A | China | 126.65 | 45.75
Kunming | N/A | China | 102.71833 | 25.03889
Nanjing | N/... | 903 | 0 | 0 | 0 | NCT00510146 | 1COMPLETED | 2010-07-01 | 2007-08-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
4
] | 122 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing. | null | Epilepsy | Epilepsy elderly seizure | null | 1 | arm 1: Open-label lamotrigine | [
0
] | 1 | [
0
] | intervention 1: Open-label | intervention 1: Lamotrigine | 63 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Gilbert | Arizona | United States | -111.78903 | 33.35283
Litchfield Park | Arizona | United States | -112.35794 | 33.49337
Phoenix | Arizona | United States | -112.07404 | 33.44838
Phoenix | Arizona | United States | -112.07404 | 33.44838
Fresno | California ... | 121 | 0 | 0 | 0 | NCT00516139 | 1COMPLETED | 2010-07-01 | 2007-08-01 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 260 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). | null | Non-Small Cell Lung Cancer | null | 2 | arm 1: Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum
Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum arm 2: Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum
Drug:... | [
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: 500 mg/m\^2, IV, q 21 days x 6 cycles maximum intervention 2: 75 mg/m\^2, IV, q 21 days x 6 cycles maximum intervention 3: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum | intervention 1: pemetrexed intervention 2: docetaxel intervention 3: carboplatin | 20 | Ballarat | Victoria | Australia | 143.84957 | -37.56622
Frankston | Victoria | Australia | 145.12291 | -38.14458
Wendouree | Victoria | Australia | 143.82838 | -37.53078
Bunbury | Western Australia | Australia | 115.64137 | -33.32711
Barretos | N/A | Brazil | -48.56778 | -20.55722
Goiânia | N/A | Brazil | -49.25389 | -... | 211 | 0 | 0 | 0 | NCT00520676 | 1COMPLETED | 2010-07-01 | 2007-10-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
5
] | 457 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstructive pulmonary disea... | null | Pulmonary Disease, Chronic Obstructive | null | 2 | arm 1: Oral inhalation once daily of placebo matching tiotropium via handihaler arm 2: Oral inhalation once daily of 18mcg tiotropium via handihaler | [
2,
0
] | 2 | [
0,
0
] | intervention 1: Oral inhalation once daily of 18mcg tiotropium via handihaler intervention 2: Oral inhalation once daily of placebo matching tiotropium via handihaler | intervention 1: tiotropium intervention 2: Placebo | 62 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Birmingham | Alabama | United States | -86.80249 | 33.52066
Jasper | Alabama | United States | -87.27751 | 33.83122
Palo Alto | California | United States | -122.14302 | 37.44188
San Diego | California | United States | -117.16472 | 32.71571
Lexington | Kentuc... | 457 | 0 | 0 | 0 | NCT00523991 | 1COMPLETED | 2010-07-01 | 2007-04-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 1,067 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this tre... | All eligible participants will receive single-blind placebo medication during the 2-week lead-in period. All participants may receive additional open-label treatment with metformin, 500-2000 mg, as needed for rescue, based on protocol specific criteria. | Type 2 Diabetes | null | 9 | arm 1: Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks. arm 2: Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks. arm 3: Participants with HbA1c... | [
0,
0,
0,
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks intervention 2: Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks intervention 3: None | intervention 1: Dapagliflozin intervention 2: Dapagliflozin placebo intervention 3: Metformin | 78 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Tempe | Arizona | United States | -111.90931 | 33.41477
Tempe | Arizona | United States | -111.90931 | 33.41477
Fresno | California | United States | -119.77237 | 36.74773
Los Gatos | California | United States | -121.97468 | 37.22661
San Diego | California | Un... | 485 | 0 | 0 | 0 | NCT00528372 | 1COMPLETED | 2010-07-01 | 2007-09-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 60 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer. | null | Carcinoma, Renal Cell | metastatic renal cell carcinoma cancer | null | 1 | arm 1: All patients were to receive 10mg everolimus (RAD001) daily. | [
0
] | 1 | [
0
] | intervention 1: take 2 tablets of RAD001 once a day by mouth (10 mg per day) | intervention 1: RAD001 | 5 | Chicago | Illinois | United States | -87.65005 | 41.85003
Peoria | Illinois | United States | -89.58899 | 40.69365
Boston | Massachusetts | United States | -71.05977 | 42.35843
St Louis | Missouri | United States | -90.19789 | 38.62727
Chapel Hill | North Carolina | United States | -79.05584 | 35.9132 | 56 | 0 | 0 | 0 | NCT00529802 | 1COMPLETED | 2010-07-01 | 2007-09-01 | University of Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 147 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis. | null | Secondary Hyperparathyroidism Dialysis | Dialysis Hyperparathyroidism Zemplar | null | 2 | arm 1: ABT-358 Zemplar arm 2: ABT-358 Zemplar | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly intervention 2: Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly | intervention 1: Paricalcitol injection intervention 2: Paricalcitol capsules | 12 | Jojutla Morelos | N/A | Mexico | N/A | N/A
Mexico City | N/A | Mexico | -99.12766 | 19.42847
Mexico City | N/A | Mexico | -99.12766 | 19.42847
Mexico City | N/A | Mexico | -99.12766 | 19.42847
Mexico City | N/A | Mexico | -99.12766 | 19.42847
Mexico City | N/A | Mexico | -99.12766 | 19.42847
Mexico City | N/A | Mexico ... | 147 | 0 | 0 | 0 | NCT00537979 | 1COMPLETED | 2010-07-01 | 2007-09-01 | Abbott | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 17 | NON_RANDOMIZED | PARALLEL | 2DIAGNOSTIC | 0NONE | true | 0ALL | false | The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with ... | Small bowel bacterial overgrowth (SBBO), an increasingly recognized malabsorptive condition caused by the excessive growth of bacteria in the small bowel, results in a spectrum of symptoms such as diarrhea, bloating abdominal discomfort and weight loss. Multiple factors both internal and external to the individual prev... | Small Bowel Bacterial Overgrowth Gastrointestinal Diseases Stomach Diseases Digestive System Diseases | SmartPill Capsule Digestive System Diseases Small Bowel Bacterial Overgrowth Gastrointestinal Device Oro-cecal | null | 2 | arm 1: Healthy Participants will report for simultaneous lactulose hydrogen breath test (H\_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal ... | [
1,
1
] | 3 | [
0,
1,
3
] | intervention 1: Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients. intervention 2: The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (... | intervention 1: Xifaxan intervention 2: SmartPill intervention 3: Lactulose hydrogen breath test (H_2BT) | 1 | Scottsdale | Arizona | United States | -111.89903 | 33.50921 | 17 | 0 | 0 | 0 | NCT00577772 | 6TERMINATED | 2010-07-01 | 2007-11-01 | Mayo Clinic | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 26 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to determine if the combination of 2 chemotherapy drugs called pemetrexed and gemcitabine might be effective treatment for head and neck squamous cell cancer. The researchers want to find out what effects, good and/or bad, that this treatment has on head and neck cancer. | Pemetrexed (500 mg/m2) and gemcitabine (1250 mg/m2) will be given together on Days 1 and 15 of a 28 day cycle in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients will not have received more than 2 prior chemotherapy regimens in the recurrent/metastatic disease setting. Vitam... | Head and Neck Cancer | Head and Neck Cancer GEMCITABINE PEMETREXED ALTIMA epidermoid/squamous cell carcinoma pharynx larynx paranasal sinus head/neck squamous cell carcinoma | null | 1 | arm 1: Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. | [
0
] | 1 | [
0
] | intervention 1: Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no ... | intervention 1: Pemetrexed plus Gemcitabine | 1 | New York | New York | United States | -74.00597 | 40.71427 | 25 | 0 | 0 | 0 | NCT00589667 | 1COMPLETED | 2010-07-01 | 2006-09-01 | Memorial Sloan Kettering Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 19 | NA | SINGLE_GROUP | 9OTHER | 0NONE | false | 0ALL | false | This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or inflammation of the gallbladder. | Hepatobiliary iminodiacetic acid (HIDA) scan scintigraphy is a nuclear medicine scan used to evaluate patients suspected of having acute cholecystitis (infection/inflammation of the gallbladder). Because it is an indirect test that looks for obstruction of the cystic duct structure, there are many causes for a false-po... | Cholecystitis | Cholecystitis FDG PET/CT HIDA scan | null | 1 | arm 1: 19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(ch... | [
0
] | 1 | [
0
] | intervention 1: Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration | intervention 1: 18FDG (an FDA-approved radiopharmaceutical) | 1 | Los Angeles | California | United States | -118.24368 | 34.05223 | 19 | 0 | 0 | 0 | NCT00590395 | 1COMPLETED | 2010-07-01 | 2007-07-01 | Alan D. Waxman, M.D. | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 168 | RANDOMIZED | CROSSOVER | 1PREVENTION | 0NONE | true | 1FEMALE | true | A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) is an oral, FDA-approved, anti-HIV drug, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the adherence and acceptabili... | It is necessary to monitor both the adherence and blood levels of microbicides in order to gauge its efficacy in a study population. Utilizing an experimental microbicide (tenofovir gel) and an anti-HIV drug (TDF), this study will measure the adherence and acceptability to and blood levels of the two interventions in t... | HIV Infections | Microbicide HIV Seronegativity | null | 6 | arm 1: Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20 arm 2: Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and va... | [
0,
0,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: 300 mg tablet daily intervention 2: 1 gm/100 ml of 1% gel vaginally daily | intervention 1: Tenofovir disoproxil fumarate intervention 2: Tenofovir gel | 7 | Birmingham | Alabama | United States | -86.80249 | 33.52066
The Bronx | New York | United States | -73.86641 | 40.84985
Cleveland | Ohio | United States | -81.69541 | 41.4995
Pittsburgh | Pennsylvania | United States | -79.99589 | 40.44062
Durban | KwaZulu-Natal | South Africa | 31.0292 | -29.8579
Durban | KwaZulu-Nata... | 504 | 0 | 0 | 0 | NCT00592124 | 1COMPLETED | 2010-07-01 | 2008-06-01 | National Institute of Allergy and Infectious Diseases (NIAID) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 18 | RANDOMIZED | CROSSOVER | 0TREATMENT | 3TRIPLE | false | 0ALL | false | This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of pregabalin and tramadol SR in a cross-over clinical study design. | null | Pain | null | 3 | arm 1: None arm 2: None arm 3: None | [
2,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: BID intervention 2: Dose 75 mg titrated to 150 mg, bid intervention 3: Dose 50mg titrated to 200 mg, bid | intervention 1: Placebo intervention 2: Pregabalin intervention 3: Tramadol SR | 2 | Portsmouth | Hampshire | United Kingdom | -1.09125 | 50.79899
Solihull | West Midlands | United Kingdom | -1.78094 | 52.41426 | 52 | 0 | 0 | 0 | NCT00610155 | 1COMPLETED | 2010-07-01 | 2008-09-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 40 | RANDOMIZED | PARALLEL | null | 2DOUBLE | false | 0ALL | false | We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prio... | null | Seasonal Allergic Rhinitis | null | 2 | arm 1: 2 weeks of treatment arm 2: 2 weeks of treatment | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 2 puffs in each nostril once a day for 2 weeks intervention 2: 2 puffs in each nostril once a day for 2 weeks | intervention 1: mometasone furoate nasal spray intervention 2: placebo | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 40 | 0 | 0 | 0 | NCT00618332 | 1COMPLETED | 2010-07-01 | 2008-04-01 | University of Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This placebo-controlled trial will test the effectiveness of Seroquel XR™ for the treatment of cocaine dependence in non-psychotic individuals who are cocaine dependent. | Cocaine abuse continues to be an epidemic. Co-morbid psychiatric disorders and high risks behaviors compound the morbidity, economic costs, and social destruction associated with this public health crisis. This is a 12 week, prospective, intent-to-treat, double-blind, randomized, placebo-controlled study of Seroquel XR... | Cocaine Dependence Cocaine Abuse Cocaine Addiction Drug Abuse Substance Abuse | cocaine quetiapine fumarate dependence abuse addiction treatment | null | 2 | arm 1: Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as... | [
0,
2
] | 3 | [
0,
0,
5
] | intervention 1: At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 40... | intervention 1: quetiapine fumarate intervention 2: Matched Placebo intervention 3: Cognitive-behavioral Therapy | 1 | Tacoma | Washington | United States | -122.44429 | 47.25288 | 60 | 0 | 0 | 0 | NCT00631748 | 1COMPLETED | 2010-07-01 | 2008-02-01 | Seattle Institute for Biomedical and Clinical Research | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 48 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combin... | Primary Objectives
* To assess the overall safety of sorafenib when administered with "the 2DOC regimen" capecitabine and oxaliplatin in patients with advanced or metastatic pancreas or biliary tract cancers.
* To define the dose limiting toxicity and maximally tolerated dose of this combination.
* To assess the clini... | Pancreatic Neoplasms Bile Duct Neoplasms | advanced pancreatic and biliary tract carcinomas | null | 4 | arm 1: Cohort 1: 200mg Sorafenib+2DOC
Oxaliplatin + Oral Capecitabine + Sorafenib arm 2: Cohort 2: 400mg Sorafenib+2DOC
Oxaliplatin + Oral Capecitabine + Sorafenib arm 3: Oxaliplatin + Oral Capecitabine + Sorafeni arm 4: Oxaliplatin + Oral Capecitabine + Sorafeni | [
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water. intervention 2: Each course of oral capecitabine administration will commence following ad... | intervention 1: Oxaliplatin intervention 2: Capecitabine intervention 3: Sorafenib | 1 | Madison | Wisconsin | United States | -89.40123 | 43.07305 | 48 | 0 | 0 | 0 | NCT00634751 | 1COMPLETED | 2010-07-01 | 2008-02-01 | University of Wisconsin, Madison | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.